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Abstract 
Asthma is a heterogeneous, complex disease with clinical phenotypes that 
incorporate persistent symptoms and acute exacerbations. It affects many 
millions of Europeans throughout their education and working lives and puts a 
heavy cost on European productivity. There is a wide spectrum of disease 
severity and control. Therapeutic advances have been slow despite greater 
understanding of basic mechanisms and the lack of satisfactory preventative 
and disease modifying management for asthma constitutes a significant 
unmet clinical need. Preventing, treating and ultimately curing asthma 
requires co-ordinated research and innovation across Europe. The European 
Asthma Research and Innovation Partnership (EARIP) is an FP7-funded 
programme which has taken a co-ordinated and integrated approach to 
analyse the future of asthma research and development. This report aims to 
identify the mechanistic areas in which investment is required to bring about 
significant improvements in asthma outcomes. 
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1 Executive summary 
This manuscript describes a state-of-the-art view of the mechanisms involved 
in asthma onset, asthma progression and asthma exacerbations and is an  
outcome of the European Asthma Research and Innovation Partnership 
(EARIP: www.earip.eu).  Readers are also referred to companion EARIP 
reports including a report on phenotyping and improving precision and 
personalised medicine for asthma(1), a report on national and regional 
asthma programmes in Europe(2) and an editorial on building the case for 
more investment in asthma research in Europe(3). 
The EARIP project was established in 2013 to harmonise efforts to reduce 
mortality and morbidity from asthma by agreeing the most important research 
priorities in Europe.  The partnership has produced an evidence- and 
consensus-based list of the research priorities needed to reduce asthma 
deaths and hospitalisations(4).  This coordinated agenda for asthma research 
and innovation will be used to address this major health and societal 
challenge and will be the foundation on which future EU, national and 
international research funding programmes can transform asthma outcomes 
throughout Europe. 
International guidelines describe asthma as a chronic airway disease 
characterised by airway hyper-reactivity (AHR) caused by a range of 
processes including airway inflammation, bronchoconstriction of airway 
smooth muscle (ASM), airway infections, allergic responses, exposure to 
pollutants, exercise, stress, and nervous provocation(5). Asthma is one of the 
most common chronic long-term health conditions in Europe. It is estimated 
that the number of people aged 45 and under with asthma in Europe is over 
30 million(6). The prevalence of asthma varies substantially across the 
European Union. A key feature of asthma is reversible decreases in lung 
function, measured either as changes in peak expiratory flow (PEF), or a 
decrease in forced expiratory volume in 1 second (FEV1). Symptoms include 
dyspnoea, cough, wheeze and chest tightness. Asthma is a heterogeneous, 
complex disease with multiple clinical phenotypes that incorporate persistent 
symptoms and acute exacerbations with a wide spectrum of both disease 
severity and control (7, 8). The complex interplay between genetic and 
environmental influences that contribute to asthma pathogenesis makes 
management a significant ongoing challenge. The lack of preventative, 
curative and disease modifying management for asthma constitutes a 
significant unmet clinical need. 
Asthma is most frequently associated with onset in early life, and is increasing 
in incidence in the developed world, but can also start in adulthood (that is 
late-onset asthma)(9). Current pharmacological management approaches are 
centered on the use of symptom relievers in the form of bronchodilators, 
which may be short acting or long acting and anti-inflammatory therapies, 
predominantly glucocorticosteroids (GCs)(10), their combinations(11, 12), 
leukotriene receptor antagonists (LTRAs)(13-15) and the non-selective anti-
inflammatory and adenosine receptor antagonist, theophylline. Innovative 
novel monoclonal antibody therapies in phase II/III clinical trials or in recent 
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clinical use include antagonists of TH2 cytokines(16-20) and anti-IgE 
therapies(21-24). Sub-lingual and other immunotherapy approaches are also 
exciting, potentially disease modifying therapies(25), that require further study 
and further development. These have had varying levels of success at 
controlling asthma symptoms, improving lung function, and in particular 
reducing asthma exacerbation rates; however no therapy yet adequately 
modifies disease, is sufficiently accessible to asthma patients or could be 
considered a cure. Despite these advances, translating scientific progress to 
new treatment avenues has been slow for asthma, considering the 
innovations and development of therapies that have had substantial impact on 
disease in other fields. Significant disconnects are observed between 
objective disease severity parameters and patients’ experience of their 
disease(26, 27), and outcomes are worse in those with psychosocial 
disadvantage(28, 29), mediated by mechanisms that remain unclear. 
Behavioural problems, such as non-adherence, are common even in patients 
with severe disease(30) and associated with worse outcomes(31). 
As medical research enters the ‘omics’ era, a new challenge facing asthma 
research is how best to harness big data sets and apply them to models 
relevant to human disease, in order to benefit asthma treatment. This 
challenge is further complicated by a recent focus on asthma endotypes or 
phenotypes and personalised medicine applying novel mechanism-based 
therapies to those in which such mechanisms are active. Taking all the above 
into account it is timely to ask the question where next in asthma research? 
This report reviews current scientific knowledge (state of the art) on 
mechanisms of asthma onset, asthma progression from mild to severe 
disease and asthma exacerbation and identifies current unmet needs in 
asthma research to indicate where future research efforts should be focused.  
The important mechanisms involved in asthma onset, asthma progression 
and asthma exacerbation and the strength of the supportive evidence for each 
mechanism are summarised in Table 1. The important methodologies or 
technologies that are required to beneficially impact on asthma research in 
future years are summarised in Table 2. Key unmet needs in understanding 
asthma mechanisms that we have identified are listed in Table 3 and 
mechanisms of asthma onset, asthma progression from mild to severe 
disease and asthma exacerbation are pictorially represented in Figures 1, 2 
and 3 respectively. These are the major areas in which future investment is 
needed to drive forward asthma research to hasten progress in preventing, 
controlling and curing asthma, and in preventing and treating asthma attacks 
and their associated morbidity and mortality. 
In lay terms, these scientific goals can be better expressed as three broad 
aims that should translate into immediately understandable goals to boost:  
o Prevention (related to onset) 
o Cure or Control (related to progression) 
o Attack avoidance/treatment (related to exacerbations). 
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2 Asthma onset 
2.1 Introduction 
Asthma onset frequently occurs early in life. Lung function is reduced by 
school-age(32) and this reduction is permanent and tracks to adulthood(33, 
34). The key pathological abnormalities of asthma, including eosinophilic 
inflammation and airway remodelling also frequently develop early and may 
be established by school-age(35, 36). Therefore to achieve disease 
modification early intervention is essential. The ideal intervention would allow 
primary prevention. Disappointingly, even secondary prevention is currently 
not on the horizon.  
In order to achieve primary prevention it is necessary to accurately predict 
which child will develop asthma. Although one third of preschool children 
wheeze, only a third will go on to develop asthma(37). Unfortunately, accurate 
prediction of asthma during the preschool years remains a significant 
challenge. Many clinical prediction scores, incorporating known risk factors 
such as atopy and family history, have been proposed(38), but they are either 
applicable too late; or have a poor predictive value(39). It is known that host 
and environmental influences interact to contribute to asthma risk.  
In addition to studying disease mechanisms, following children who grow out 
of asthma and identifying differences between those who and those who do 
not at the molecular level may provide insight into mechanisms and potentially 
point towards a cure of asthma 
A further significant problem is late onset asthma, which is frequently severe, 
often appears non-atopic (absent skin–prick test positivity or raised serum 
specific IgE) in pathogenesis and which may have other risk factors, can be 
quite a difficult differential diagnosis (sometimes overlapping with COPD) and 
may represent a different disease spectrum from early onset asthma. Also 
asthma can arise in adulthood as a result of occupational and irritant 
exposures frequently resulting in non-Th2 asthma. 
Asthma is more likely to be diagnosed in people with anxiety and 
depression(40, 41). Research strategies therefore need to incorporate 
multiple risk factors and include complex interactions in order to reflect the 
disease and identify effective interventions(42). See Figure 1 for a summary 
of important mechanisms involved in asthma onset. 
2.2 Asthma onset - State of the art 
2.2.1 Viruses 
Viral infections represent critical events that likely contribute to asthma onset. 
Early life respiratory syncytial virus (RSV), human rhinovirus (RVs) and 
human metapneumovirus (HMPV) lower respiratory infections have all been 
strongly associated with progression to clinically defined asthma by age 6(43-
47). However, little is known about the mechanisms underlying the 
progression of virus-induced early wheezing to later life well-defined asthma. 
Indeed, there is considerable debate over whether these virus infections are 
important causative agents of later asthma development, and/or are markers 
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of risk for asthma development independent of causation. It is possible that 
different viruses fulfil different roles that are not obvious in the available cohort 
studies. Interactions between viral infections and underlying genetic 
susceptibility identified from Genome Wide Association Studies (GWAS) have 
been reported(45). Although this has shed light on gene-environment 
interactions, and identified several candidate genes with reproducible and 
strong associations, they remain associations and mechanistic advances are 
needed. For example polymorphisms spanning CDHR3 are associated with 
childhood asthma with severe exacerbations(48). CDHR3 encodes cadherin-
related family member 3 (CDHR3), which is involved in epithelial polarity and 
cell-cell interactions as well as being a receptor for rhinovirus C, the most 
common respiratory virus associated with asthma exacerbations and the key 
variant identified in GWAS modulates levels of CDHR3 providing a putative 
mechanism(49).  Some mechanistic evidence has come from available small 
animal models. Infection of newborn mice with RSV, and the mouse 
equivalent pneumovirus, show striking long term changes to the airway and 
induction of pro-TH2 responses to allergens later in life(50, 51). The 
interactions between virus infection with allergen exposure, and also the 
beneficial effects of environmental and airway microbes are important 
avenues to pursue for future research. (see Table 2 for an explanation of new 
methodologies in asthma research) 
2.2.2 Allergen exposure & TH2 pathways 
T helper (TH)2 immunity mediated by interleukin (IL)s -4, -5, -9 and -13 after 
sensitisation and exposure to allergens drives allergic asthma, one of the 
major subtypes of asthma, inducing IgE production, eosinophilia and tissue 
remodelling(52). Targeted therapies in subtypes of established TH2-mediated 
asthma have been successful in reducing exacerbations(53, 54). Interventions 
to prevent initial sensitisation may provide a long-lasting alternative to TH2-
targeted therapies. As yet, initiating processes are incompletely understood, 
but likely involve dendritic cells (DCs), basophils, eosinophils, innate lymphoid 
cells (ILCs) and macrophages and airway epithelial cells secreting the newly 
identified pro-TH2 cytokines IL-33, TSLP and IL-25, which thus may be 
potential alternative candidates for intervention. 
ILCs are of particular interest as they have been recently described as tissue-
resident and circulating innate immune cells(55), with three major subsets: 
ILC1s, ILC2s and ILC3s, which mirror TH1, TH2 and TH17 cells, 
respectively(56). There is little detailed information on the role of ILCs in 
asthma onset and progression, though roles for both IL-33 and IL-25, which 
act as growth factors and activators of ILC2s, have recently been proposed in 
acute exacerbations(57, 58). A particular shortcoming in our present 
understanding is information from experimental studies in humans. 
Mouse models of asthma have provided evidence for ILC2s in development of 
allergic asthma(59-61) and ILC3s in a model of obesity-associated AHR(62). 
Whether these data can be translated to asthma depends on whether these 
models truly reflect human disease. In addition, asthma is a heterogeneous 
disease with respect to onset (early versus late), response to treatments and 
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concomitant pathology (allergic versus non-allergic, obesity), which likely 
reflects differences in underlying pathobiology. So, the contribution of ILCs 
may vary between the various subtypes of asthma. There is evidence that IL-
33, IL-25 and TSLP, and their receptors, are involved in response to allergens 
and respiratory viruses(57, 58). This work provides at least preliminary 
evidence for a role of ILCs in asthma, as well as other innate and adaptive 
immune cells like eosinophils, basophils(63), mast cells and T cells, which 
may also be responsive to IL-33, IL-25 and TSLP. 
2.2.3 Air pollution 
The role of air pollution in asthma development is unclear(64). Three 
European birth cohort studies have reported positive relationships between 
traffic-related pollution and doctor-diagnosed asthma(65-67). The Southern 
Californian Children’s Health Study has reported that traffic-related pollutants 
can cause asthma in children(68, 69), as has a Dutch study in which traffic-
related pollution levels at the birth address and incidence of asthma were 
considered during the first 8 years of life(70). Exposure to nitrogen dioxide 
(NO2) and particulate matter (PM)25 at birth correlated with asthma 
development in childhood and adolescence(71) and a 5ppb increase in NO2 
levels during the first year of life with physician-diagnosed asthma (OR: 
117)(72). In women, a 36µg/m3 increase in PM25 correlated with greater 
odds (OR 120) of incident asthma, whereas a 36µg/m3 increase in PM2.5 
(OR 114) and 58ppb increase in NO2 (OR 108) correlated with incident 
wheeze(73). Not all studies, however, show such a relationship(74), and such 
inconsistencies may be due to incomplete exposure assessment or 
insufficient study power.  
A recent report from the Royal College of Physicians London summarized the 
state of the art and also states that exposure of young children to second-
hand tobacco smoke remains one of the most important sources of indoor air 
pollution and is associated with asthma prevalence, although the effects of 
exposure to maternal smoking in pregnancy may be stronger than for 
childhood exposure(75). Occupational exposures as well as second-hand 
smoking may also be related to late onset adult asthma. 
Host characteristics that have been reported to influence the effects of air 
pollution on asthma development include nutritional status, atopy, and social 
stress(76-82). Polymorphisms in glutathione S-transferase (GSTP1) that 
facilitates the elimination of reactive oxygen species have also been 
associated with a greater risk of asthma(83) and sensitisation to allergen in 
association with traffic-related NOx during the first year of life (84). As the 
environment is a potentially modifiable factor in asthma development(64), 
funding is urgently needed to study the effects of the environment on asthma 
development, to reveal new approaches to reduce future development of 
asthma.   
2.2.4 Bacteria & the microbiome 
During and immediately following birth neonates are exposed to microbes that 
progressively colonize the gut, the skin and airways. Indeed, within a very 
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short time frame post-partum, one moves from being 100% human, to a 
human super organism that lives with vast numbers of microbes(85, 86). 
Although much research to-date has focused on the gut, host-microbe 
interactions in the lung may also be powerful determinants of the presence or 
absence of asthma(87).  
The human microbiome describes the totality of microorganisms (bacteria, 
viruses, fungi and parasites) associated with the human body, in both health 
and disease. Molecular techniques that include 16S rRNA gene sequencing, 
microbial whole genome sequencing and metagenomics are revolutionising 
our understanding of the diversity and function of the human microbiome(88, 
89). The lower airways are now known to carry a characteristic community of 
microorganisms (90-92) with a similar density of bacteria to the upper 
intestines(91).  
Presence of certain bacteria may be protective or harmful. A rich microbial 
environment in early life is associated with protection against development of 
asthma and allergies(93-95) and the protection appears to be mediated via 
signals transmitted via innate immune signalling(95). Molecular studies have 
since shown that particular genera, such as Bacteroidetes and Actinobacteria 
appear to be protective(91, 96). In support of the above, experimental animal 
models have shown that the early life formation of the lung microbiome 
provides signals to the immune system that shape its maturation and 
influences susceptibility to asthma(97-99). Several studies have reported that 
past exposure to tuberculosis or BCG vaccination may be associated with 
protection from development of asthma and allergies(100, 101), though others 
do not agree(102) and causal relationships in man are difficult to 
establish(103). Preclinical studies with BCG and bacterial products derived 
from Mycobacterium tuberculosis have shown protection from eosinophil 
recruitment and AHR in mouse models of allergic airway inflammation(104, 
105). 
It is clear that the microbiome influences the trajectory towards or away from 
asthma(106), so how could this be harnessed to reduce the onset of asthma? 
Spending the first year of life in a farming environment leads to a reduced risk 
of asthma and allergies(107). This protection is associated with increased 
microbial diversity(94), and could be related to bacterial components that are 
inhaled, as exposure of the lung to farm dust and endotoxin protect against 
house dust mite-induced asthma through A20 induction in lung epithelial 
cells(108) or to the constituents of the raw cow’s milk(109). This latter 
observation may be particularly relevant from the standpoint of future 
interventions. In addition to a high microbial load, raw cow’s milk contains a 
plethora of ‘prebiotics’, that is to say ‘energy sources’ for bacteria, which can 
support bacterial growth and function in the gut.  Early life nutrition, and 
perhaps maternal nutrition, are key areas where more research is needed in 
order to identify strategies through which early life microbial exposure and 
colonization can be shaped. Answering which microbial signals, when and 
how we can provide them, holds the potential for reducing the onset of 
asthma. 
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Molecular investigations also reveal that the bronchial microbiota in asthma is 
rich in pathogens(91, 110-114) (typically Proteobacteria such as Moraxella, 
Neisseria and Haemophilus spp.). Birth cohort studies have shown that the 
presence of the same pathogens in throat swabs predicts the later 
development of asthma(115), and that these bacteria have been associated 
with asthma exacerbations(116). A recent study applying 16S rRNA 
sequencing of the nasopharynx microbiome of 234 children in their first year 
of life showed that transient infections of Streptococcus, Moraxella, or 
Haemophilus were associated with virus-associated acute respiratory 
infections. Importantly, asymptomatic infection with Streptococccus was a 
predictor for asthma(117). The role these bacteria play is still unclear, and 
additional studies show that they may be independent risk factors for acute 
wheezing episodes in young children aged <3 years, as well as viruses(118). 
The interactions between viruses and bacteria to promote wheeze and 
asthma onset are largely unexplored. 
Finally the role of antibiotics remains widely debated. While the maternal use 
of antibiotics has a dose-related association with the risk of asthma in 
offspring(119); there is evidence for efficacy of antibiotics in the treatment of 
asthma and related syndromes(120-123). The idea that the microbiome 
represents both harmful and protective genera, that help shape the early 
immune system; and that bacteria have a dual role in initiating and protecting 
against disease, may partly explain this controversy. 
2.2.5 Diet & hormones 
The prevalence of obesity has more than doubled since 1980, such that it is 
now the commonest nutritional disorder worldwide(124). The concomitant rise 
in the prevalence of asthma triggered speculation that obesity may be 
causally related to asthma incidence. Obesity is a major risk factor for asthma 
development, with the strength of association greater in females than in 
males(125). However, understanding of the pathophysiological mechanisms 
underlying this relationship remains incomplete. 
Cluster analyses have identified two phenotypes of obesity-related asthma 
(ORA) distinguished primarily by age of onset(126). The early onset 
phenotype is characterised by classic, TH2-driven inflammation, and is 
complicated by the subsequent development of obesity(126). Conversely, the 
late onset phenotype is typically non-atopic, exhibits lower markers of TH2 
inflammation, occurs more frequently in women and develops consequent to 
obesity(127). Little is understood about how obesity may affect asthma onset. 
The increased AHR observed in late onset ORA is likely multifactorial with 
contributions from mechanical, inflammatory, metabolic and dietary factors in 
addition to co-morbidities such as gastro-oesophageal reflux disease and 
sleep-disordered breathing. Studies to enhance comprehension of the 
mechanisms underpinning ORA onset should be prioritised to facilitate the 
development of phenotype-specific therapies.  
Evidence suggests that obesity and asthma share common developmental 
origins(128). Common genetic, epigenetic, maternal and pre-natal factors may 
predispose to both conditions by influencing in utero foetal programming. 
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Subsequent early-life events and exposures in the post-natal period may 
subsequently modify this risk. Further research efforts are warranted to help in 
the prevention of the development of both disorders. 
We are cognisant of the fact that we have not adequately addressed the roles 
of a number of other dietary factors including vitamins, oxidants/anti-oxidants, 
fatty acids etc, in asthma onset. For example epidemiological evidence 
highlights strong associations with vitamin D status(129, 130), assessed as 
circulating levels of 25-hydroxyvitamin D, with an increased incidence, 
severity and poor control of asthma(131), and these data appear strongest in 
children(129, 130). A recent Cochrane systematic review concluded that 
vitamin D is likely to reduce the risk of severe asthma exacerbation and 
healthcare use(131). Two large trials of vitamin D supplementation in 
pregnancy show strong trends for improvement of respiratory outcomes in the 
infant(132, 133), through likely effects on lung maturation, appropriate 
immune system development and improved handling of respiratory infections. 
Vitamin D and oxidants are additionally addressed in part in the following 
section, but further research into these factors and their roles in asthma 
prevention are also needed, including further clinical studies of vitamin D 
throughout the life course.  
Further studies on the roles of fatty acids are also clearly needed, as a recent 
study on the effects of n-3 long-chain polyunsaturated fatty acids (fish oil) vs 
placebo (olive oil) in the third trimester of pregnancy reduced the absolute risk 
of persistent wheeze or asthma at three to five years of age in the offspring by 
31%, with a greater reduction of 54% seen in offspring of mothers whose 
blood levels of eicosapentaenoic and docosahexaenoic acid were in the 
lowest third of the trial population at randomization(134). 
2.2.6 Immune reactivity vs immune tolerance 
Immune tolerance is an active process involving specialised regulatory T-
lymphocyte (Treg) subsets(135, 136). The airways are continuously exposed 
to harmful and non-harmful environmental antigens and in health these elicit 
immune responsiveness to achieve the effective handling of pathogens, but 
importantly also immune regulation to prevent potentially damaging immune 
responses to non-harmful antigens(135-137).  
Allergic asthma is provoked by inhalation of otherwise innocuous aero-
allergens such as house dust mite, mouse, cockroach, cat and dog 
proteins(138) accompanied by a lack of immune tolerance, leading to 
inappropriate immune responses to these harmless allergens. A major CD4+ 
Treg population expresses the transcription factor Foxp3; young boys with a 
rare, X-linked, genetic mutation causing loss of Foxp3+ Tregs, suffer from 
multisystem autoimmunity, and severe atopy including eczema, food allergy, 
and eosinophilic inflammation, highlighting the importance of Foxp3+ Tregs in 
preventing aberrant immune responses to allergens in early life(139). A 
second major Treg population synthesizes the anti-inflammatory cytokine IL-
10. Blood cells from individuals with severe allergy/asthma show reduced IL-
10 synthesis in response to allergen stimulation(136, 140). 
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Inappropriate immune responses/breaches of immune tolerance can result 
from failure in generation of Tregs, or inhibition of their actions, and both can 
be influenced by the environment. For example, vitamin D promotes both IL-
10+ and Foxp3+ Tregs(141), whilst air pollution is associated with impaired 
Foxp3+ Treg function(142). Many other environmental factors, such as 
smoking and oxidative stress, can stimulate production of mediators that 
inhibit the action of Tregs(143). The manner in which antigen is presented by 
dendritic cells (DCs) also profoundly affects the immune response, including 
whether effector or regulatory lymphocyte responses are generated, and DCs 
are similarly affected by environmental factors(144, 145). The inappropriate 
immune response to innocuous allergens in asthma causes further immune 
dysregulation as the TH2-biased allergic response inhibits antiviral 
responses(146). 
Understanding critical mechanisms of development of naturally occurring 
immune tolerance offers the potential for early life interventions to dramatically 
reduce the incidence of allergies(147). The same potential therefore exists for 
asthma. Funding is needed to study the effects of the environment on immune 
regulation, and to reveal new approaches to reduce future development of 
asthma. 
2.2.7 Psycho-social and behavioural factors 
Although frequently unrecognized, psychological dysfunction (particularly 
anxiety) is up to 6 times as common in people with asthma as in matched 
controls(28, 148) including in children, with evidence of a bi-directional 
relationship, in that although asthma may induce anxiety, anxiety may also 
precede asthma. Longitudinal cohort studies in adults have reported that the 
presence of anxiety and panic significantly increased the odds of subsequent 
asthma(40) , and a birth cohort study reported that behavioural problems in 
the child at the age of 3 yrs. was a significant risk factor for both a subsequent 
asthma diagnosis and for late-onset wheezing(148). The mechanisms 
underlying this relationship are not understood, although it is known that 
stress can have significant but complex effects on immunological 
function(149). Psychological stress can affect the release of cortisol and the 
expression of inflammatory mediators in a complex and time-dependent way, 
with increased airway inflammation associated with stress(150). There is 
some evidence that psychological stress may predispose to the development 
and severity of atopic conditions, including asthma, through effects on the 
immune system(151). Although it is clear that stress can result in measurable 
neuroimmunological effects that can be associated with asthma expression 
and morbidity, the precise significance of these biological effects and the 
ways in which they interact with other stress-related factors such as health 
beliefs and behaviours is not fully understood(151). 
2.3 Addressing the unmet need 
The study of early life asthma onset presents some unique challenges that 
separate it from stable asthma progression and asthma exacerbation. A great 
unmet need in understanding mechanisms of asthma onset is the lack of 
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available complex mouse models that accurately reflect human asthma 
development in early life. Allied to this are the difficulties in obtaining valuable 
early-life human samples from human birth cohort studies to validate findings 
in the models.  
The discovery of age appropriate, efficacious interventions in preventing 
asthma onset is completely dependent on the development of age appropriate 
models that will allow discovery of critical mechanisms. Not only are some 
susceptibility genes different for childhood and adult onset asthma(152, 153), 
but the effects of immune maturation and lung development must also be 
considered(98). Effective prevention strategies that are clinically translatable 
will only become apparent if data is obtained from correct animal models and 
validated in early life/childhood studies of asthma onset. This is highlighted by 
the stark differences in allergic airways disease that result depending on age 
at first allergen exposure in mice(98). The significantly different responses 
that result from allergen exposure at different ages can also be explained by 
influences of the developing airway microbiome and the maturing immune 
system. Recently marked differences between human adult and neonatal 
immune systems have been highlighted by the demonstration of a unique 
group of CXCL8/IL-8 producing T cells in preterm babies that were particularly 
at risk of infections(154). Immune mechanisms that predict neonatal infection 
have also been investigated using a systems biology approach and 
investigating immune-metabolic networks in babies(155). Blood volumes as 
small as 0.5-1ml were sufficient to identify a 52 gene cluster; predictive of 
bacterial infection. However, an accurate prediction was only achieved when 
immune and metabolic pathways were integrated, emphasising the need to 
use complex models, and combine information accordingly.  
Any distinction between the mechanisms of early- and adult-onset asthma 
may reflect not so much differences in the host response but in the timing of 
first exposure to an aetiological allergen.  For example, certain types of 
occupational asthma – arising through specific IgE-associated responses to 
protein allergens encountered only in the workplace – appear clinically and 
mechanistically to be indistinguishable from atopic asthma acquired early in 
life.  Moreover, there is good evidence that the incidence of occupational 
asthma can be related directly to the levels of allergen exposure in the 
workplace; and that the disease can be effectively controlled by reducing such 
exposures(156). 
There is a similar dearth of complex mouse models that accurately reflect 
human asthma development in later life. Also allied to this are the difficulties 
in obtaining valuable human samples from human cohort studies in adulthood, 
or studies of incident late onset asthma, to validate findings in the models.  
Another need is that of lower airway samples from accurately phenotyped 
patients (representing all the different asthma phenotypes/subtypes) and 
controls, from which meaningful information can be obtained from relatively 
small sample sizes(35, 157, 158). We also need to determine the degree to 
which information from more easily accessible peripheral blood or nasal 
airway samples, reflects lower airway changes. Mechanistic studies that allow 
manipulation of contributory factors and truly reflect human disease are 
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needed, but currently are not being undertaken. In children, this is likely 
because of the difficulties inherent in obtaining appropriate tissue samples 
that allow functional analyses to be performed. One example of circumventing 
these limitations is the identification of asthma susceptibility genes through 
large scale, multi-centre studies that have incorporated patients from different 
cohorts, with data analysis being performed by a single centre with the 
required expertise(159). This approach of collaboration and getting access to 
the targeted patients and specific sampling from multiple centres and ensuring 
the correct expertise in processing and analysis also needs to be adopted to 
allow mechanistic advances from more invasive or difficult samples.  Although 
this approach to some extent does not differentiate the different phenotypes 
or endotypes and may lead to some genes being missed. Combined GWAS 
plus expression quantitative trait loci (eQTL) analysis for different phenotypes 
or endotypes may provide solutions. 
The use of novel techniques that allow detailed information to be obtained 
from small and limited samples while challenging, is not impossible. These 
include single cell transcriptome profiling(160) and multi-component 
immunohistochemistry. Models using human cells also need to be innovative 
and optimally reflect in vivo conditions. Utilisation of co-cultures of epithelial 
cells or their supernatants with leukocytes(57, 161) will improve functional 
information obtained. The limitations of animal models are recognised(162) 
but if efforts are made to optimally reflect human conditions by allowing for 
critical factors such as age, route of allergen exposure, appropriate species 
and strain findings can be translated(163). 
With respiratory viral infections likely being important in asthma onset, an 
important unmet need in asthma onset is how best to target these viruses. 
Palivizumab is an anti-RSV antibody effective in reducing RSV induced 
bronchiolitis and it may reduce subsequent wheezing(164-166). Recently, two 
new oral RSV antivirals performed well in double-blind, placebo-controlled 
studies of experimental RSV infection in healthy subjects, showing impressive 
reductions in symptom score and virus load(167, 168). Development of new 
small molecule inhibitors or other anti-virals that can be used in early life or 
childhood is an area that must receive further support. 
The role of non-pharmacological approaches to asthma prevention, including 
environmental manipulations and psycho-social approaches, remains 
uncertain. 
3 Progression of stable asthma  
3.1 Introduction 
Mechanisms that promote disease activity and progression in established, but 
stable asthma overlap with, but may also be distinct from, those involved in 
asthma inception, and may thus require different scientific insights and 
treatments. This next section deals with stable asthma and asthma 
progression including the dynamics of the microbiome, and whether 
modifications may serve as future useful therapeutic targets, the process of 
Page 17 of 91 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
© Copyright 2016,  GA- 602077 
EARIP Consortium   Version: Final 
 
   
 17  
 
airway remodelling and its impact on lung function over time, the role of 
airway nerves, of adverse effects of asthma treatments and of disease 
modifying therapies such as anti-TH2 cytokine biologics, the identification and 
mechanisms of other non-TH2 asthma endo-phenotypes, and 
immunoregulatory processes such as resolution of airway inflammation and 
the development of immunological tolerance. See Figure 2 for a summary of 
important mechanisms involved in asthma progression and severity. 
 
3.2 Progression of stable asthma - State of the art 
3.2.1 Bacteria, fungi & the micro/mycobiome 
Detection of pathogenic Proteobacteria, particularly Haemophilus spp., are 
more frequent in bronchi of asthmatics than controls(91). Only 3/11 adult 
asthmatic subjects had severe asthma, though all were on inhaled 
corticosteroids (ICS). Similar data have been reported in other studies and the 
bacterial burden correlated with AHR(110), longer asthma disease duration, 
lower FEV1 and higher sputum neutrophils(112). In another study in sputum in 
severe and non-severe asthma Bacteroidetes and Fusobacteria were reduced 
in non-severe and severe asthmatic groups compared to healthy controls, 
Proteobacteria were more common in non-severe asthmatics compared to 
controls (OR=2.26) and Firmicutes were increased in severe asthmatics 
compared to controls (OR=2.15). Among Firmicutes, Streptococcal OTUs 
were associated with recent onset asthma, rhinosinusitis and sputum 
eosinophilia(169). 
Potentially pathogenic bacteria have also been identified by culture in sputum 
of 15% of subjects with stable asthma and this was associated with greater 
airway inflammation(170), while in stable severe asthma, sputum was positive 
for bacteria in 52% of patients(171). IgE positivity to Staphylococcus aureus 
enterotoxin was significantly greater in patients with severe asthma (59.6%) 
than in healthy controls (13%) and enterotoxin IgE-positive subjects had 
increased risk of severe asthma (OR, 11.09; 95% CI, 4.1-29.6), greater oral 
steroid use and hospitalizations and lower FEV1(172). Further case-control 
studies identified patients with severe asthma with non-tuberculous 
mycobacteria (NTM) infections, and infected subjects were older, had lower 
FEV1, and had used ICS for longer than controls(173, 174). Additionally roles 
for the atypical bacteria Mycoplasma and Chlamydophila pneumoniae in 
asthma pathogenesis have long been postulated, as reviewed in(175, 176), 
however data to date are inconclusive and further work is needed to better 
understand the possible contribution of these organisms to asthma 
pathogenesis. 
There is clear evidence of increased susceptibility to bacterial infections in 
asthma. Increased risk (~3-fold) of invasive pneumococcal disease in non-
severe asthma has been confirmed in two separate studies(177, 178), while 
that risk increases to 12-fold in severe asthma(177). Studies of mechanisms 
of increased susceptibility to bacterial infection in asthma report that toll-like 
receptor (TLR)5 and TLR7 expression is decreased in the lung in severe 
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asthma, thus severe asthmatics may suffer from insufficient TLR signalling 
during bacterial infections leading to impaired defense mechanisms(179-181). 
Effective antibacterial immunity requires type II IFN-γ and Th1 immune 
responses and mouse model data report that host defense against bacteria is 
also mediated by type I IFNs(182, 183). There is extensive data that type I, II 
& III IFN induction by viral and bacterial stimuli is deficient in asthma and that 
deficiency relates to underlying asthma severity(180, 184-188). IL-12 and IL-
18 induction by LPS in macrophages are also deficient in asthma(186, 189, 
190) and these are important for induction of IFN-γ and Th1 immune 
responses. Reduced phagocytosis of bacteria is reported in patients with 
severe asthma, thus persistence of bacteria in the lower airways in asthma 
may result from this defect(191). The mechanisms for increased susceptibility 
to bacterial infections in asthma are only partially understood, and further 
research in this field is clearly needed. The role ICS play in this increased 
susceptibility also needs further investigation. 
The microbiota in established asthma is different to that in health(91), and 
recent preclinical evidence argues that the airway microbiota found in 
diseased lungs can influence chronicity and progression of airway 
inflammation(192), while treatment with certain microbes or their products, 
can reduce asthma severity(108). Microbial manipulation has been 
spectacularly successful in treating bowel inflammation(193, 194), and if 
asthma is driven by airway dysbiosis then manipulation of the airway 
microbiota may also ameliorate disease progression.   
A pragmatic and potentially highly effective means of controlling asthma 
progression could be via the diet. A diet high in fermentable fiber fed to adult 
mice was effective at reducing the severity of allergic airway inflammation via 
fermentation of dietary fiber by gut microbiota, which directed the immune 
system away from allergic responses(195). The logical next steps are 
intervention studies in humans, where individuals would eat a diet high in 
fermentable fibers, or to receive supplements of certain downstream 
metabolites generated following microbial fermentation of fiber (e.g. short 
chain fatty acids). Alternative approaches whereby individuals are exposed to 
bacteria (probiotics) and/or their substrates (prebiotics) with the goal of 
directing an individual’s immune system away from asthma, hold promise.  
Fungal sensitisation and long term fungal infection/colonisation are associated 
with increased asthma severity and complications such as bronchiectasis and 
chronic pulmonary aspergillosis. Estimates suggest that many million people 
have severe asthma with fungal sensitizations and allergic bronchopulmonary 
aspergillosis and a substantial proportion of adult asthmatics attending 
secondary care have fungal sensitization. Little is known about which fungi 
and fungal allergens are relevant to asthma pathogenesis, and there is little 
data on the most effective management strategies. Further studies are 
needed on fungal exposure, sensitisation and infection/colonization and the 
role of host defense against fungi in asthma, as well as studies on the role of 
the mycobiome and of effective interventions(196). 
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3.2.2 Virus infections 
Virus infections precipitate the great majority of asthma exacerbations and 
exacerbation frequency in asthma is strongly correlated with rates of decline 
in post-bronchodilator lung function (FEV1)(197-199) and loss of 
bronchodilator reversibility(198). It therefore seems likely that virus induced 
exacerbations likely lead to structural alterations in the lung, and permanently 
worsened airflow and poor health status, and although the mechanisms are 
unclear, the effects are likely long lasting and may be irreversible(200). It is 
not known whether impaired host defense against virus (and bacterial) 
infections is associated with progression from mild to severe asthma. 
3.2.3 Air pollution 
There is substantial evidence linking traffic-related air pollution, exposure to 
second hand smoke and occupational exposures to progression of both 
allergic and non-allergic asthma to severe disease and perhaps to COPD. 
Diesel exhaust heightened lower airway eosinophilic inflammation in allergic 
subjects(201) and timing and duration of traffic-related air pollution exposure 
were found to be effect modifiers as early-life traffic related exposure 
correlated with persistent wheezing (OR 2.31) in children(202). The first 8 
years of life represent a susceptible period, as exposure to traffic-derived 
particulate matter (PM) in that period has been associated with impaired lung 
function growth(203). Furthermore, in a study of asthmatic patients walking on 
a London polluted street for 2 hours, the reduction on FEV1 and the degree of 
neutrophilic lung inflammation observed after the walk was associated most 
consistently with exposures to ultrafine particles and elemental carbon, and 
the reduction in FEV1 was greater in the moderate compared to the mild 
asthmatics(204). Fine particulate matter was associated with increased 
respiratory resistance in children(205) and lifetime exposure to PM10 and NO2 
was associated with retarded lung volume growth in elementary-school age 
children(206). However, since no specific pollutant or combination conferred 
more detrimental effects, it is important to use multi-pollutant models to 
analyse these associations(207). Many developing countries still employ open 
fires for cooking, which correlated with greater risks (OR 212) of asthma 
symptoms in children(208). The detrimental effects of pollution are readily 
demonstrated in certain subgroups. Young males are 3-times more likely to 
have asthma symptoms associated with exposure to truck traffic-related air 
pollution than those without(209), whereas being overweight (OR 436) or 
obese (OR 306) increases susceptibility to exercise-related asthma 
symptoms associated with exposure to PM25(210). 
Mechanistic experimental exposure studies point to interactions between 
diesel exposure and allergen, in increasing airway inflammation(201) and 
suggested a possible mechanism contributing to epithelial wall damage 
following allergen exposure(211). 
Epidemiological evidence supports a role for air pollutants in contributing to 
the spread of respiratory viral infections(212). This may be relevant to the 
mechanisms by which increased ambient ozone, nitrogen dioxide, PM2.5 and 
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sulphur dioxide levels are associated with increased admission for asthma 
exacerbations particularly in children(213). 
3.2.4 Airway nerves & neural pathways 
The role of airway innervation in asthma and the potential contribution of 
neuronal dysfunction to asthma pathophysiology are rarely studied. Human 
airways are richly innervated by parasympathetic efferent nerve fibres, as well 
as various sensory (afferent) nerve fibres(214), whereas contribution from the 
sympathetic nervous system is scant(215, 216). Afferent airway nerve 
activation mediates the noxious sensations patients associate with asthma 
e.g. chest tightness, air hunger, airway irritation, congestion and 
breathlessness(217) but also initiates reflexes producing cough, 
bronchospasm, AHR and mucus hypersecretion. Neuronal dysfunction 
therefore has the potential to play a major role in the pathogenesis of asthma 
symptoms. 
Dysfunction of afferent and efferent nerves plays a major role in the 
pathogenesis of airway obstruction and AHR in pre-clinical asthma 
models(218-222)  and in a major asthma symptom, cough(223). Cough in 
asthma is the archetypal airway reflex and is not only a common(224) and 
troublesome symptom(225), but is also associated with disease severity(226) 
and poor prognosis(227). Of the symptoms experienced by asthma patients 
cough is also the most readily objectively quantified and thus can provide 
insights into neuronal dysfunction. Recent work suggests that different airway 
diseases including asthma exhibit differing cough responses to a range of 
inhaled tussive agents, suggesting distinct neuro-phenotypes can be 
identified(223). Moreover, compared with healthy controls, different 
phenotypes of mild/moderate stable asthma exhibit heightened cough 
responses to the inhaled irritant capsaicin, which directly activates vagal 
afferent fibres. These responses were most exaggerated in females with non-
atopic asthma, suggesting neuronal dysfunction may be particularly relevant 
in non-Th2 disease(228). Cough responses were unrelated to treatment with 
inhaled corticosteroids, exhaled nitric oxide, airflow obstruction or AHR, also 
supporting the hypothesis that neuronal hyper-responsiveness is a key 
feature contributing to treatment-resistant and non-allergic phenotypes.  
Defensive respiratory reflexes, such as cough and bronchospasm, are 
regulated by vagal afferent nerves(229-232). Ion channels on the termini of 
airway sensory fibres located under the airway epithelium make them capable 
of directly responding to a diverse range of agents, many of which correspond 
to triggers of asthma symptoms identified by patients, including changes in 
temperature, humidity, pollution and irritant chemicals such as cigarette 
smoke, cleaning products, perfumes etc(229, 233 ), as well perhaps to 
changes in airway calibre during bronchospasm(234), Neuronal dysfunction in 
animal models of asthma can also be induced by eosinophils(235), 
viruses(236) and mediators such as neurotrophins(237, 238) and can mediate 
induction of AHR by β2 agonists(239).  
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Gastroesophageal reflux disease and a history of rhinitis or sinusitis are 
clearly identified risk factors for development of severe asthma(240), however 
the mechanisms involved are poorly understood, and the possible 
involvement of neural pathways requires further study. 
The importance of nerves in asthma is highlighted by the effectiveness of 
muscarinic antagonists in the treatment of asthma(241, 242), blocking reflex 
bronchospasm mediated by acetylcholine release from parasympathetic 
efferent airway fibres. Animal models of asthma have demonstrated that in 
addition to anti-muscarinics, the late response to inhaled allergen can be 
prevented by blockade of afferent sensory nerves(220), implicating airway 
nerve function in allergic as well as irritant induced asthma symptoms. 
Although translation in clinical allergen challenge studies is still required. Of 
note AHR, airway obstruction and cough often persist despite treatment with 
highly effective anti-inflammatory drugs, perhaps as a consequence of 
persisting neuronal dysfunction(221). Therefore, there is a need for further 
research on the role of nerves in the pathogenesis of asthma and on new 
therapeutic approaches targeting neural dysfunction in this disease.  
A substantial proportion of new or relapsing asthma in adulthood can be 
attributed to exposures encountered in the workplace(243).  The paradigm of 
occupational asthma induced by classic allergic responses to workplace 
proteins such as flour or detergent enzymes is evidence that age itself is no 
protection against the development of IgE-associated respiratory disease.  A 
substantial proportion of occupational asthma, however, arises in response to 
exposure to chemical agents that are of too low a molecular mass to act alone 
as antigens.  In some cases these agents appear to conjugate with human 
proteins to form a hapten-protein allergenic complex; in many others this 
appears not to be the case and other mechanisms, such as neuronal 
dysfunction acquired through repeated exposure to respiratory irritants require 
exploration. The public health implications may be substantial since irritant 
exposures encountered at work – by, for example cleaners who consistently 
report high rates of asthma-like symptoms to cleaning products (244), or 
swimming pool attendants who regularly encounter chlorine(245) – can have 
very significant ‘down-stream’ effects in consumers. 
Research on the role of nerves in asthma has been hampered by the different 
innervation of murine and human airways(246), by limited access to neuronal 
tissues (nerve fibres or ganglia) from patients with asthma, and by 
methodological challenges in analysis of these tissues. Therefore, more 
funding is needed for neuronal studies of human tissues, such as analysis of 
nerves in human whole-mount biopsies(216), to provide urgently needed data 
on the precise nature of airway innervation in asthma(162). In addition, 
experimental non-murine eg guinea pig asthma models are needed to provide 
more relevant functional information on airway nerves in asthma(247-249). 
Models and reagents in other species such as rats, rabbits and dogs would 
also aid both safety and efficacy studies. Finally, clinical studies of emerging 
therapies specifically targeting neuronal dysfunction in asthma(250, 251) are 
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needed to identify new therapeutic opportunities(223). 
3.2.5 Airway remodeling 
Airway remodeling represents one of the most challenging problems in asthma 
and is linked to disease progression. Airway remodeling includes epithelial cell 
shedding, goblet cell hypertrophy, basement membrane (BM) thickening and 
ASM cell hyperplasia, leading to progressive decline in lung function(252, 
253). Another prominent feature of lower airway remodeling is increased 
vascularization that correlates with airflow limitation and AHR(252, 253). 
Growing evidence suggests that inherent changes in lung-resident cells are 
the principal drivers of fibrotic processes. Support for this concept comes from 
studies demonstrating that airway remodeling is observed in preschool 
children without signs of inflammation, and is comparable to that documented 
in adults(252, 253). 
Other mechanisms involved in promoting airway remodeling processes include 
notch2(254), IL-13(255), the gamma-aminobutyric acid system(256), 
transcription factors regulating goblet cell differentiation(257) and many 
others. Further studies investigating mechanisms involved in promoting airway 
remodeling processes are required to lead to better therapies to prevent its 
development. Once developed, novel therapeutic approaches such as 
bronchial thermoplasty can ameliorate severity(258), however mechanisms 
involved are poorly understood, and better understanding of these 
mechanisms could lead to less invasive approaches to ameliorate severity. 
Mainstay anti-inflammatory therapies, such as ICS, do not significantly affect 
airway remodeling processes, emphasizing the notion that uncontrolled 
structural changes may be a cause as well as a consequence of progressing 
asthmatic disease and future funding should be channeled to studies aiming to 
dissect the mechanisms involved(259, 260). Large-scale proteomic and 
genomic profiling of lung-resident cells may also guide the identification of 
novel mechanisms for airway remodeling. In addition, mathematical modeling 
approaches aimed at elucidating the effects of ASM contraction and the 
causes of altered airway mechanics in asthma may greatly facilitate the 
understanding of airway remodeling pathogenesis(259, 260). 
Immune cells infiltrating the airways of asthmatics are potent sources of pro-
fibrotic factors, including transforming growth factor (TGF)-β, and therefore a 
role for immune cells in promoting structural changes is likely. In fact, 
eosinophils are a rich source of TGF-β and eosinophil depleted mice are 
protected from peri-bronchial collagen deposition and increased ASM mass in 
response to chronic allergen exposure(259). Recent studies have also 
uncovered key roles for other TGF-β superfamily members, including activin-
A, and bone morphogenic proteins and the epithelial cell-derived cytokines, IL-
33, TSLP and IL-25, in airway remodeling in asthma(261-263). Hence, the 
development of biologics targeting the effects of these cytokines on the control 
of airway remodeling represents a fruitful avenue for future research that may 
be translated to better treatment options for asthmatics(262, 263).  
A major hindrance in our understanding of the mechanisms underlying airway 
remodeling is the lack of animal models that can effectively recapitulate 
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structural changes(252, 253). It is, thus, essential that future funding should be 
targeted on the development of better animal models and novel in vitro assays 
that incorporate multiple cell types and mimic the intrinsic mechanical forces 
occurring in the airways. Finally, studies investigating the effects of 
environmental changes, such as diet and microbiota composition, on airway 
remodeling are warranted and future funding should be channeled in this area. 
3.2.6 Immune reactivity vs immune tolerance 
Because development of tolerance to allergens depends on the context 
(including dose, timing and route of exposure as well as presence of co-
exposures such as LPS) of exposure to the environmental antigens, this is 
amenable to therapeutic manipulation. The best example of this is allergen 
immunotherapy, which involves administering allergen to patients to induce 
long-term, allergen-specific, immune tolerance. This can be achieved by 
injection immunotherapy, which has been shown to induce benefits lasting 
long after treatment has stopped(264), but which requires repeated 
attendance at allergy clinics for 3 years. This can also be achieved by 
sublingual immunotherapy(25), which is newer and therefore has unknown 
duration of long-term benefit, but which has the advantage of being 
administered by the patient at home. 
Allergen immunotherapy increases Treg frequency and particularly of those 
Tregs that synthesize IL-10(265). Efforts are ongoing to standardize 
immunotherapy protocols, improve safety and efficacy, reduce costs and 
duration of treatment, and to better understand immune mechanisms involved 
to further improve its utility in treating asthma(265). Further current challenges 
in immunotherapy include understanding how to maintain immune tolerance 
and memory regulatory cell populations over extended periods of time.  
If factors that underlie loss of such immune tolerance in asthma can be 
identified by research, then future therapies and environmental policies can 
be formulated to tackle the underlying immune dysregulation in asthma. 
Research is needed to study mechanisms underlying loss of immune 
tolerance and dysregulation in different asthma endotypes with the aim of 
designing better targeted treatments that restore normal immune responses, 
reducing asthmatic inflammation without the side-effects of suppressing 
healthy immune responses as seen with high dose corticosteroids. As the 
environment is a potentially modifiable factor in immune dysregulation, 
funding is also needed now to urgently study the effects of the environment on 
immune regulation, to reveal new approaches to treat asthma.   
3.2.7 Resolution of airway inflammation 
Chronic inflammation underlies the pathogenesis of asthma, the intensity of 
symptoms and progression of disease. Yet, efforts to tackle chronic 
inflammation in asthma have mostly explored the activation of anti-
inflammatory or immunoregulatory responses on the assumption that the 
dampening of pro-inflammatory responses would suffice for inflammation to 
fade away.  
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Recently, it has become apparent that resolution of inflammation is by itself an 
active and highly orchestrated process, of similar complexity to the onset and 
progression of inflammation, responsible for the catabolism of the 
inflammatory response, the egress of immune cells and the restoration of 
tissue homeostasis(266). Among the multiple pathways involved, the 
production of specialized pro-resolving lipid mediators (SPMs) such as 
resolvins, protectins and maresins seems to be particularly important(267). 
These are generated through complex biosynthetic pathways from ω-3 and ω-
6 polyunsaturated fatty acids and act in a stereospecific manner through G 
protein-coupled receptors to reverse vasodilation and suppress leukocyte 
infiltration, de-activate inflammatory cells, promote apoptotic cell and tissue 
debris clearance and repair damaged tissue(267). 
In asthma, emerging evidence suggests that SPMs play a prominent role in 
the resolution of airway inflammation(268). SPM networks are altered in 
exhaled breath condensate, bronchoalveolar lavage, sputum or blood of 
patients with asthma(269-273), while administration of synthetic SPMs such 
as lipoxin A4, protectin D1, resolvin D1 (RvD1) or resolvin E1 (RvE1) 
promotes resolution of airway inflammation in experimental mouse 
models(271, 272, 274-278). SPMs pro-resolving actions in this context may 
additionally involve activation of macrophage efferocytic function and 
suppression of TH2 cytokines, IgE and ILC2 function, although their spectrum 
of activities remains largely uncharacterized(268). This raises the possibility of 
a key role of SPMs in the termination of airway inflammation with significant 
implications for the therapeutic potential of these molecules in halting asthma 
progression. This largely unexplored area is therefore in need of urgent 
funding. 
3.2.8 Adverse effects of asthma therapies 
β2-agonists are almost universally used therapies in asthma as single agents, 
and as combination therapy with ICS. Inhaled short (SABA) and long acting 
(LABA) β2-agonists mediate their protective effects by inducing cyclic 
adenosine monophosphate (cAMP) in smooth muscle cells (SMCs) leading to 
smooth muscle relaxation and thereby, bronchodilatation. Although β2-
agonists have undoubted beneficial effects, safety concerns have been 
repeatedly raised regarding the use of SABAs and LABAs in asthma.  
Regular use of SABAs four times daily in stable asthma results in worse 
asthma control than use only when needed to relieve wheezing(279, 280) and 
overuse of SABAs (without ICS) in asthma exacerbations has been 
repeatedly associated with increased risk of hospitalisation or mortality(281, 
282). LABA use without ICS has also been linked to increased asthma 
mortality(283-285) and the FDA has cautioned medical providers about risks 
associated with LABA use without ICS(286). The fact that LABA use, when 
combined in the same inhaler with an ICS, is safe was confirmed in two recent 
large studies in both adults(287) and children(288). Concerns about use of β2-
agonists in the absence of ICS persist as excessive use of SABAs in the 
absence of ICS was recently identified in 40% of deaths and use of LABAs 
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without ICS in 5(282). The mechanisms behind these safety concerns and the 
mechanisms through which ICS therapy is protective are poorly understood.  
Fenoterol is a SABA linked with an epidemic of asthma mortality in the 
1980s(289) and reductions in hospitalisations due to asthma exacerbations 
following withdrawal of fenoterol suggested this was due to a beneficial effect 
of withdrawal on asthma severity(290). 
β2-agonists relax smooth muscle by raising levels of cAMP in SMCs. 
However, the most numerous cells in the airway and the cells most accessible 
to inhaled β2-agonists are not SMCs, but bronchial epithelial cells (BECs) and 
airway macrophages. It therefore seems likely that respiratory adverse effects 
of β2-agonists might be mediated via effects on these cells.  
The pro-inflammatory cytokine IL-6, is induced in BECs by β2-agonists alone, 
and importantly in relation to overuse of β2-agonists in asthma exacerbations, 
IL-6 induction by RV infection was further augmented by β2-agonists. 
Promoter studies revealed that LABA augmentation of RV-induced IL-6 
occurred via a cAMP response element (CRE) in the IL-6 promoter(291), 
indicating that an adverse effect of β2-agonists is mediated via cAMP 
elevation in BECs, just as their beneficial effects in SMCs are.  
Two independent clinical trials have confirmed induction by β2-agonists of the 
asthma-related mediators brain-derived neurotrophic factor (BDNF)(292) and 
matrix metalloprotease (MMP)-9(293) in humans and both mediators are 
induced via cAMP/CREs(294, 295). Many other pro-inflammatory mediators 
with potential adverse effects in asthma have CREs in their promoters and are 
therefore likely to be induced by β2-agonists including IL-17, COX-2, 
amphiregulin, MMP-2, MUC5AC, MUC5B and MUC8(296). However, these 
have not to date been studied with β2-agonists. A genome-wide study 
suggests the number of human genes potentially inducible by β2-agonists via 
CREs in their promoters might extend into the hundreds(297). Thus β2-
agonists have the potential to induce many genes implicated in asthma 
pathogenesis. 
Induction of and augmentation of RV-induced IL-6 by LABA were both 
abolished by ICS(291). ICS also blocked LABA induction of BDNF both in 
vitro and in vivo(292). IL-17, MMP-2, MUC5AC and MUC8 are all suppressed 
by steroids(296). These data suggest that use of β2-agonists/ICS in 
combination inhalers would result in the ICS component blocking direct 
genomic adverse effects of β2-agonists while maintaining the beneficial 
bronchodilator effects(296). This interpretation supported by the 
demonstration that taking both together, combined in a single inhaler, is 
clearly safe(287, 288). Mechanistic studies investigating adverse effects of β2-
agonists and protective effects of ICS in BECs and airway macrophages in 
vitro, and in vivo in people with asthma, to identify genes induced by β2-
agonists and suppressed by ICS, are urgently needed. 
Use of leukotriene receptor antagonist (LTRA) therapy has been associated 
with an increased incidence of Churg-Strauss syndrome (CSS)(298). How 
LTRA therapy may interact with the pathogenesis of CSS is unknown. 
Potential mechanisms for an association between LTRAs and the CSS have 
been postulated including potential for allergic/hypersensitivity drug reactions 
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and leukotriene imbalance resulting from leukotriene receptor blockade. 
Further studies monitoring incidence of CSS in asthma patients receiving 
LTRAs are needed, including studies on the possible role of steroid/ICS 
withdrawal. Mechanistic studies investigating how LTRA therapy may interact 
with the pathogenesis of CSS are also needed. 
Inhaled corticosteroids are widely used in chronic obstructive pulmonary 
disease (COPD) and their use is associated with an increased risk of 
pneumonia, but the mechanisms of this effect remain unclear(299). There is 
clear evidence of increased susceptibility to bacterial infections in 
asthma(177, 178), but this increased risk has not been directly linked to ICS 
use. The mechanisms for increased susceptibility to bacterial infections in 
asthma and the role ICS plays in this increased susceptibility are poorly 
understood. ICS also suppress antiviral immunity in the absence of 
asthma(300), and are associated with impaired innate IFN responses in 
asthma(301), but ICS also reduce exacerbation frequency(302), the majority 
of which are induced by viruses. Therefore, ICS presumably have mixed 
effects in asthma, and the mechanisms involved clearly need better 
understanding in order to guide future drug development. 
Human genetics research will be critical to the development of genetic profiles 
for personalised medicine in asthma. Genetic profiles that predict individual 
disease susceptibility and risk for progression, may predict which 
pharmacologic therapies will result in a maximal therapeutic benefit, and may 
also predict whether a therapy will result in an adverse response in a given 
individual. Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-
adrenergic receptor pathways have identified genetic loci associated with 
therapeutic responsiveness(303). Future studies, are needed to identify 
genetic profiles permitting personalised approaches to maximize therapeutic 
benefit for an individual, while minimizing the risk for adverse events. 
3.2.9 Diet & hormones 
Obesity has been associated with both over and under diagnosis of 
asthma(304), and with worse asthma control, impaired response to ICS 
therapy, increased exacerbation frequency, increased healthcare utilisation 
and diminished asthma-specific quality of life relative to normal-weight 
asthma(305). Patients with obesity-related asthma (ORA) are more likely to 
have obesity-related comorbidities such as obstructive sleep apnea and 
gastroesophageal disease that can influence responsiveness to asthma 
therapies(306). Obesity, although reportedly not associated with airflow 
obstruction(307), adversely affects pulmonary mechanics by reducing lung 
tidal volume, functional residual capacity and AHR(308), however, the 
mechanisms involved require clarification. Additional studies addressing the 
effect of obesity on airway remodelling may also help identify novel 
therapeutic targets.   
Obesity is associated with chronic, low-grade, systemic inflammation and 
adipose tissue produces numerous pleiotropic adipokines in addition to 
serving as an energy-storage depot(309). The two most widely studied 
adipokines are leptin (pro-inflammatory) and adiponectin (anti-inflammatory) 
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and both have been implicated in the pathogenesis of ORA(309). However, 
our understanding of the roles of adipokines within obese airways warrants 
further research. Adipokines are promising therapeutic targets as they are 
differentially expressed in obesity and several have been shown to exhibit 
immunomodulatory effects(309). 
Although obesity is a state generated by positive calorie imbalance, dietary 
constituents, such as ω-3 and ω-6 polyunsaturated fatty acids and saturated 
fats, may also affect ORA pathogenesis(310). Furthermore, insulin resistance 
and oxidative stress may also play an important role(311). In addition to 
enhancing AHR obesity is thought to potentiate airway inflammation and 
reactivity to environmental stimuli such as ozone and particulate matter(127), 
with associated negative consequences on asthma control. Results from 
recent mouse studies have emerged to suggest potential mechanisms(312); 
however, further work is required. 
The most rational strategy to improve the health status of individuals with 
ORA is weight reduction and several studies have demonstrated 
improvements in pulmonary function, asthma control, health status, AHR and 
systemic and airway inflammation following weight loss interventions(313, 
314). However, whilst weight optimisation confers many health benefits and is 
recommended in the treatment of ORA, randomised controlled trial (RCT) 
data evaluating the efficacy of weight loss interventions (both surgical and 
non-surgical) in ORA are limited(315).  
Evidence addressing the optimal pharmacological strategy for the treatment of 
ORA is lacking. Practical ORA management is complicated by the vicious 
cycle generated by obesity-induced poor asthma control and corticosteroid-
associated weight gain. Greater understanding of the mechanisms 
underpinning obesity-associated corticosteroid resistance (in addition to 
promotion of weight-loss strategies) is key to breaking this cycle and 
improving clinical outcomes. Thus further work in this area should be 
prioritised.  
Asthma is more common in males from birth until puberty(316, 317) but 
becomes more prevalent(318, 319) and more severe(320, 321) in women 
after puberty. Women are more likely to develop difficult-to-treat or steroid 
refractory asthma(317) and women >25 years of age account for >62% of 
hospitalisations and 64% of asthma deaths(317, 322). In addition to puberty, 
menstruation(323), pregnancy(324, 325), menopause(326, 327) and oral 
contraceptive use(328) have been associated with asthma outcomes in 
women(317). Peri-menstrual cyclic changes in lung function have been 
reported in women(329) and asthma symptoms and peak expiratory flow can 
deteriorate during high levels of oestrogens(330). These data suggest a role 
for sex hormones, most likely a pathogenic role for oestrogen and most 
immune cells involved in asthma express the oestrogen receptors (ER) ERα, 
ERβ. The hypothesis that sex hormones play a role in the pathogenesis of 
asthma is further supported by the higher prevalence of asthma in women 
with early menarche(331) which is associated with higher oestrogen 
concentrations(332). Oestrogen levels have also been associated with the 
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incidence of asthma(333) and women with a history of asthma who use oral 
contraceptives have reduced risk of current wheeze(334). But there are also 
developmental differences: female foetal lung development is more rapid than 
that of males(335) and male lungs are smaller with fewer respiratory 
bronchioles at birth(336) while at puberty boys have ~25% higher lung 
volumes than girls of identical height(337) and lung function development 
ends earlier in girls than in boys(338). Understanding gender differences in 
asthma which might in part be regulated by sex hormone levels appears 
important to optimize individualized treatment. Furthermore, a better 
understanding of gender differences in asthma pathogenesis and progression 
might lead to new treatment modalities. 
Among the chronic diseases of adolescence, asthma has the highest 
prevalence and health care usage(339). During puberty children experience a 
shift in cognitive abilities from more concrete to more abstract thinking(340, 
341) and children with asthma feel more lonely and depressed compared to 
healthy peers(342). Absenteeism or poor school performance can disrupt 
peer relationships and endanger development of independence(341). While 
self-care generally increases in children it may decrease again in 
adolescence(341, 343). Girls are more likely to incorporate asthma into their 
social and personal identities compared to boys who try to avoid this(344). 
Age and low emotional quality of life correlate with body mass index and level 
of asthma symptoms(341). Thus, in addition to hormonal changes discussed 
above which influence asthma severity, developmental changes in cognition 
and behaviour during puberty can severely affect asthma outcomes. Most 
management interventions do not account for the challenges faced by 
psychosocial and physiologic needs during puberty(341) and age specific 
programs are needed(341). Such programs could have vast influences on the 
future course of individual patients’ asthma and could be instrumental in 
improving long term outcomes.  
Around 10% of women of childbearing age suffer from asthma(325). Asthma 
prolongs time to pregnancy and has negative effects on fertility that increase 
with age and asthma severity(345). Pregnancy is associated with a large 
increase in circulating oestrogen levels that drop to baseline levels after 
delivery. The course of asthma during pregnancy is variable with 
approximately 1/3 reporting unchanged asthma control, 1/3 an improvement 
and 1/3 worsening asthma(325). Analysis of pulmonary function versus 
symptoms suggests that some reported deteriorations in symptoms might not 
be reflected in changes in airway function(325, 346). A small increase in the 
risk of congenital malformations in the offspring of patients with asthma has 
been reported with a higher incidence in more severe asthma(325). Preterm 
labour, low birth weight, small for gestational age and preeclampsia have 
been associated with pregnancies in women with asthma(325). 
Understanding mechanisms that lead to deteriorations of asthma control 
during pregnancy and programs to monitor asthma control during pregnancy 
have a potential to avoid adverse outcomes during pregnancy. 
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3.2.10 Psycho-social and behavioral factors 
Despite advances in pharmacotherapy that are theoretically capable of 
achieving high levels of asthma control for most patients, asthma outcomes 
have remained suboptimal and many patients remain symptomatic despite 
intensive pharmacological therapy. Psychological conditions such as anxiety 
and depression are common in people with asthma and associated with poor 
control(28). Consistent evidence from cross-sectional surveys using a variety 
of methodologies suggests that symptomatic asthma control and asthma-
related health status are impaired when anxiety or depression are also 
present(29, 347-349). This relationship is independent of confounding factors 
such as age, gender, socio-economic status, objective asthma severity and 
prescribed treatment level, with one study(349) estimating that the presence 
of psychiatric co-morbidity accounted for 29% of the variance in Asthma 
Control Questionnaire score. Anxiety and depression are associated with poor 
asthma outcomes across a range of different outcome measures. These 
include impaired asthma-related quality of life(350, 351), higher asthma-
related health resource utilisation(352), increased asthma-related health 
costs(352) and increased use of rescue medication(353). Patient reported 
outcomes correlate poorly with objective physiological measures of asthma 
control, while measures of psychological state are strongly predictive of most 
outcomes. The mechanisms underlying these associations are not well 
understood, and there is a paucity of interventional studies to show whether 
the recognition and treatment of co-morbid psychological dysfunction is 
effective in improving asthma control, with variable evidence supporting other 
behavioural interventions. 
Breathing control exercises now have ever-increasing evidence to support 
their use as an adjuvant treatment for those uncontrolled on standard 
pharmacotherapy and are advocated in guidelines(354, 355), although the 
mechanism of action is incompletely understood. Behavioural interventions to 
support adherence(356) and internet-based behaviour change and self-
management support interventions for asthma show promise(357) but require 
further research to clarity which patients may benefit and in the optimal format 
of delivery. An accurate multidisciplinary assessment of adherence and 
psychological state are considered key parts of the multidimensional 
phenotyping of asthma required in a difficult asthma clinic before embarking 
on expensive treatment with new biological therapies. Other non-
pharmacological interventions (including relaxation, mindfulness, biofeedback 
and cognitive-behavioural based) have some supportive evidence but an 
inadequate evidence-base and mechanisms of effectiveness are generally 
poorly understood(358). In view of how commonly the co-morbidity between 
psychological problems and asthma occurs, it is perhaps surprising that the 
evidence base for treatment is so meagre 
To effectively complement pharmacological asthma management, there is a 
need to understand the neurocognitive, affective and behavioural 
mechanisms that impact asthma outcomes, particularly those relevant to 
anxiety and depression. Breathlessness is the fundamental symptom of 
asthma, with brain processing pathways possessing a strong affective 
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component that can cause anxiety and enhance symptom perception(359) as 
well as negatively impacting cognition and behavioural coping 
mechanisms(360). Neurocognitive studies have reported activation in the 
ventrolateral periaqueductal gray (vlPAG) associated with respiratory 
threat(361) and prefrontal activity may reflect stress-related 
inflammation(362). Investigation of neural pathways in asthma shows 
differential responses to a cognitive task in subgroups with different levels of 
inflammatory response to an allergen challenge, suggesting the possibility of 
neurophenotypes for asthma, with the potential of targeted interventions(363). 
Differential neural reactivity is related to disease severity in brain areas 
related to emotion-processing, indicating that neurophenotypes may exist 
within asthma populations. Such neurocognitive evidence supports cognitive-
behavioural models(364) suggesting that some people with asthma may have 
dysfunctional cognitions (e.g. symptom perception) that interact with 
physiological mechanisms leading to the increased asthma onset risk noted in 
longitudinal studies. Cognitive-affective models have emphasized the 
importance of symptom perception in reduced asthma-specific quality of 
life(364). Anxiety is the strongest predictor of the unpleasantness of 
breathlessness during bronchoconstriction in people with asthma(365), and 
anxiety has a stronger relationship with asthma-related health status than lung 
function(366). 
Understanding of the mechanisms underpinning these relationships is needed 
to efficiently design and target appropriate interventions. 
3.3 Addressing the unmet need 
New therapies and emerging biologicals now target TH2 asthma phenotypes, 
with success, showing that disease modifying agents have efficacy, even 
though asthma is clearly established. Limited information exists regarding 
other asthma endo-phenotypes particularly non-TH2 asthma and treatment-
resistant phenotypes. Therefore, novel approaches incorporating pre-clinical 
and clinical models are required in order to develop new therapeutic 
approaches for these neglected varieties of asthma.  
Many of the agents known to precipitate asthma symptoms are also capable 
of activating airway nerves leading to the hypothesis that neuronal 
hyperresponsiveness is a key feature of some asthma endotypes, contributing 
to treatment-resistant phenotypes, particularly in non-TH2 asthma. The role of 
airway innervation has received very little attention to date and has the 
potential to identify novel therapeutic targets. Major investment in consortia 
aimed at understanding and treating severe asthma has focused on 
inflammatory profiling in the various sub-phenotypes identified with little 
investment in the characterisation of neuronal function and associated targets. 
Anti-IgE and IL-5-targeted therapies are currently finding their place in the 
treatment of asthma. A word of caution may be required as long-term effects 
are unknown as yet. And further, both eosinophils (depleted by anti-IL-5 and 
anti-IL-5 receptor) and basophils (depleted by anti-IL-5 receptor) may exercise 
protective properties and thus their depletion may cause unwanted effects. A 
major challenge for these interventions will be to decide optimal timing of their 
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use, particularly as sensitization and the start of asthma progression 
frequently occurs early in life. While much effort is put in obtaining antibodies 
that are highly effective, it should also be considered that dampening 
responses might be effective and at the same time may preserve useful 
functions of the targeted mediator. Thus, while anti-TH2 cytokine therapy will 
continue to impact on stable asthma and perhaps on asthma progression, 
there is still a lot of basic information missing on the best way to harness 
these therapies. 
The successes with TH2-targeted therapy indicate that this approach is viable 
in the treatment of asthma in which these pathways are active. Intervention 
with the inhibition of TH2 responses is still in its infancy and development 
would be greatly helped by relevant animal models. Efforts like U-BIOPRED 
and SARP, to obtain detailed molecular insights into various endotypes and 
phenotypes of severe asthma, should be pursued in parallel with the 
development of animal models to substantiate the functional relevance of 
specific molecular pathways for specific endotypes.  
Airway epithelial cells and macrophages are an important source of IL-25, IL-
33 and TSLP, which act on TH2 cells, ILC2s and DCs to enhance TH2 
responses and we need to clarify whether epithelial cells and macrophages 
from individuals with asthma produce greater amounts of these TH2-promoting 
cytokines compared to those without disease. We also need to develop 
inhibitors of IL-25, IL-33 and TSLP(367) to permit comparisons of their relative 
abilities to inhibit TH2 cell, ILC2 and DC mediated enhancement of TH2 
responses. These studies will need to be carried out in pre-clinical models to 
permit greater understanding of their biology, as well as in RCTs with detailed 
phenotyping, to permit better understanding of which sub-phenotypes of 
asthma might respond to each therapy. Blocking these pathways holds great 
promise, as this should block TH2 responses more effectively than targeting 
individual TH2 cytokines, and they should also be more broadly applicable 
across different asthma phenotypes. Recent studies have also revealed that 
ILCs show plasticity. ILC1s can trans-differentiate into ILC3s, and vice 
versa(368) and ILC2s into ILC1s and vice versa(369). Therefore trans-
differentiation is an option for restoring the balance between ILC subtypes and 
with that adjust effector responses. 
There is a need for more intensive investment in mechanisms of resolution of 
inflammation. Key areas that will need to be investigated include the more 
global lipidomic analysis of ω-3 and ω-6 polyunsaturated fatty acid-derived 
lipid mediators, the better understanding of their regulation and biological 
functions at the ‘system level’, the effect of age, diet, environmental influences 
and infections in their generation, and their deregulation during disease. The 
identification of asthma subtypes that would most likely benefit from SPMs, 
and the development of appropriate therapeutic agents with desirable 
pharmaceutical properties will ultimately determine whether such rational new 
treatments aiming at pushing inflammation ‘forward’ towards its resolution can 
bring about significant improvements in asthma outcomes.  
Studies analysing the effects of the disease itself, as well as treatments such 
as ICS on host immunity against viral and bacterial infections in asthma are 
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urgently needed. These should include ex vivo studies in human primary cells 
as well as in vivo studies in models of asthma, investigating the effects of 
disease/ICS on host defense against virus and bacterial infections in BECs, 
macrophages and dendritic cells. Human experimental rhinovirus infection 
should be used to determine whether virus infection alters the microbiome 
and impairs host immunity to bacteria in patients with asthma. This model 
would then offer a model to study the effects of disease/ICS on the 
interactions between virus infection, host immunity, and the microbiome in 
small numbers of patients over a short period. By comparison of the effects of 
virus infection between asthmatic/healthy patients and patients using ICS and 
ICS-naive patients, experimental rhinovirus infection has the potential to 
identify mechanisms of increased susceptibility to viral/bacterial infections 
related to disease itself and to ICS use. Studies are also needed to 
investigate relationships between viral and bacterial infections and 
progression from mild to severe asthma, as well as studies on host immunity 
against these infections and asthma progression. 
In relation to air pollution, the observation that exposure to traffic-derived PM 
during the first 8 years of life can impair lung function growth(203) must make 
us focus on the mechanisms by which traffic related air pollution, as well as 
perhaps work related exposures and second hand smoking may increase the 
severity of asthma. Epidemiological studies need to be pursued to find out 
whether there is any threshold safe levels of exposure or not in this respect. In 
addition, we need to find out what determines susceptibility to adverse 
consequences of exposure, the cellular and molecular mechanisms involved, 
and to devise and test preventive measures and treatments (for those 
particularly susceptible), as the problem of pollution will take time to be 
controlled at source. We need genome wide association studies (GWAS) and 
epigenetic studies in exposomics, and extension of these studies into asthma 
in particular, to better understand how asthma underlies increased 
susceptibility to stressors like cigarette smoking, occupational exposures and 
traffic related (eg. diesel exposure) and other sources of pollution. 
We need to refine the understanding of mechanisms underlying the worsening 
of asthma progression with particular focus on oxidative stress pathways, TH2 
and non-TH2 pathways (including the role of sensory nerves). We need to 
determine whether there is a particular endotype of asthma that results from 
high susceptibility to pollutant effects and we need to establish treatments 
(and life style measures eg dietary) to combat the effects of pollutants on 
asthmatic diathesis in the most susceptible individuals. 
Studies are additionally needed to determine whether direct induction by β2-
agonists via cAMP, as well as potentiation by β2-agonists of virus-induction, of 
pro-inflammatory mediators in airway epithelial cells and macrophages, may 
explain the adverse effects of β2-agonists in stable asthma and in asthma 
exacerbations. These studies should be carried out in vitro using human 
primary cells from people with asthma and should use methods such as whole 
genome transcriptomics or RNA-seq to identify all genes which are up-
regulated by β2-agonists. Further studies should test the hypothesis that these 
adverse effects will be resolved by the addition of ICS. Similar studies should 
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be carried out in vivo, in people with asthma with both LABAs and SABAs 
delivered alone at therapeutic doses and should sample airway lining fluid 
using the novel method of bronchosorption to measure soluble mediators, as 
well as airway BECs and macrophages for gene expression analyses. Again 
these studies should include β2-agonists alone, and β2-agonists in 
combination with ICS. Such studies are urgently needed to better inform 
safest use of these ubiquitous therapies. 
A major hindrance in our understating of the mechanisms underlying airway 
remodeling is the lack of animal models that can effectively recapitulate 
structural changes. This is due to the disparities in lung morphology between 
species and to the fact that most of the experimental protocols utilized are 
tested as preventive, rather than therapeutic, approaches(252, 253, 259). It is, 
thus, essential that future funding should be targeted to the development of 
better animal models, to mapping of different models to different asthma 
phenotypes and development of novel in vitro assays that incorporate multiple 
cell types and mimic the intrinsic mechanic forces occurring in the airways. In 
addition, more attention should be directed to the contribution of the 
remodeling of the small airways in asthma, the mechanisms of which remain 
incompletely defined. 
For the microbiome, future studies are required to establish the range of 
commensals and Proteobacteria spp., fungi and other pathogens in the lower 
airway microbiome of normal and asthmatic subjects, to establish the degree 
of individuality, stability and anatomic variability of airway microbial 
communities, to relate the microbiota to severity and duration of asthma, 
current therapy, and measures of inflammation and prospectively study the 
effects of antibiotics on the asthmatic airway microbiome. Further work in pre-
clinical models as well as in man is needed to understand the role of 
probiotics, prebiotics and the gut microbiome in regulating allergic airway 
inflammation and asthma. Finally, studies investigating the effects of 
environmental changes, such as diet and microbiota composition, on asthma 
progression are warranted and future funding should be channeled in this 
area. Pragmatic approaches, such as diet changes, have the potential to 
rapidly be tested and implemented, and consequently represent an 
opportunity for influencing asthma progression in the medium term. To 
achieve this, directed funding ensuring high quality and rigorous clinical 
intervention studies is needed.  
Better understanding of the mechanisms underpinning the relationship 
between psychological and neurological factors and asthma outcomes is 
needed to help clinical care and to understand the complexity of asthma. The 
effectiveness of psychological and non-pharmacological interventions and the 
way such interventions fit in with pharmacological strategies need to be 
established, and the mechanisms of effectiveness need to be understood to 
allow efficient targeted delivery of appropriate interventions to the right 
patient. Patients consistently stress the need for a holistic approach and for 
better integration of non-pharmacological strategies, and a personalised 
medicine approach demands that a holistic strategy encompassing these 
factors be established. 
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4 Asthma exacerbations 
4.1 Introduction 
Asthma exacerbations are universally accepted as the major cause of asthma 
morbidity, they contribute hugely to the healthcare costs associated with 
asthma and they are responsible for unacceptable asthma mortality(370). The 
pharmaceutical industry, academia and governing bodies all recognise the 
important impact of asthma exacerbations and the need for new asthma 
treatments that specifically address the burden of asthma exacerbations(5).  
Respiratory viral infections precipitate the vast majority of asthma 
exacerbations, however a number of other factors also contribute to 
exacerbation risk including allergen exposure(302, 371), air pollution(372), 
bacterial infection/reactivation(118, 373), eosinophils(374, 375), total 
IgE(376), asthma severity(377), genetic background(49, 159), 
dampness(378), temperature variation(379), vitamin D deficiency(380, 381) 
medication adherence(382), absence of health insurance(377) and risk 
perception(383). Indeed, identification of other precipitants of asthma 
exacerbation is key to reduce asthma morbidity and health care utilization. 
Additional studies of risk scores for asthma exacerbation may help guide 
management of asthma patients(384, 385) while predictors of hospitalization 
and/or relapse in patients already experiencing an exacerbation are also 
being examined(386). See Figure 3 for a summary of important mechanisms 
involved in asthma exacerbations. 
 
 
4.2 Asthma exacerbations - State of the art 
4.2.1 Viruses 
In adults and children, respiratory viruses cause approximately 80% of 
asthma exacerbations. The most common precipitants are RVs, but all 
respiratory viruses can do so. The roles of respiratory viruses, which may 
work both additively/synergistically with other stimuli including allergens and 
pollutants(302, 371, 372), and bacteria and atypical bacteria which are also 
important triggers of asthma exacerbation have been extensively covered in 
other recent reviews(387-389). 
Interferons (IFNs) are anti-viral cytokines that induce >300 individual genes 
which aim to limit virus replication and dissemination(390). Many studies have 
reported deficient type I (β) and type III (λ) IFN production in BECs cultured 
from both children and adults with asthma, in response to RV infection(157, 
180, 184, 185, 187, 391, 392). Studies have been extended to include IFN-α, 
other viruses/viral mimics and other cell types including airway 
macrophages(185, 393), peripheral blood mononuclear cells(301, 394), and 
blood derived DCs(395, 396). The degree to which this deficiency relates to  
asthma severity and/or control(301), or is found only in certain asthma 
phenotypes, but not others(397, 398), requires further study.  
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Impaired IFN responses in asthma are thought to be caused at least in part, 
by increased expression of the negative regulator suppressor of cytokine 
signaling (SOCS)-1(399). Various cytokines including IL-4, IL-13(146) and 
TGF-β(400, 401) can suppress virus-induced IFNs in vitro, however whether 
this is solely dependent upon SOCS1 remains to be established. Additionally 
TLR7 (a viral RNA sensor and potent IFN-inducer) expression(179, 180) and 
function(402) are reported to be deficient in asthma. Further studies on 
mechanisms of IFN deficiency in asthma are required. 
Augmenting deficient IFN production in asthmatic patients could be a novel 
approach for therapeutic intervention in the treatment of virus induced asthma 
exacerbations. Recently, inhaled recombinant IFN-β therapy was studied in 
naturally occurring colds in mild-moderate asthmatics and it reduced 
moderate/severe exacerbations, symptoms and improved lung function in a 
sub-group of moderate asthmatics(403). Whether or not IFN-β was acting as 
an anti-viral cytokine, and/or was also effective due to antagonistic properties 
on TH2 cytokine pathways(404, 405) is currently unclear. Azithromycin has 
been shown to augment IFN responses during RV infection and reduce viral 
load in vitro(406). This property of azithromycin however has not been 
confirmed in clinical trials. 
Neuronal dysfunction in asthma can be amplified by respiratory viral 
infections(407), but this is an area that requires further investigation to 
determine the degree to which this is important in man. 
4.2.2 Bacteria, fungi & the microbiome 
Bacteria are also associated with asthma exacerbations, specifically the 
atypical bacteria (Mycoplasma (M.) and Chlamydophila (C.) pneumoniae) with 
serological positivity rates as high as 40-60% in some studies(175, 373, 408-
410), indicating that viral and atypical bacterial infections may act together to 
increase the risk of asthma exacerbations. 
While asthmatics have increased susceptibility to respiratory bacterial 
infections(177, 178, 411), increased carriage of pathogenic respiratory 
bacteria identified by culture(412) and molecular techniques(91), in depth 
microbiome studies pre and post asthma exacerbation in longitudinal studies 
are lacking. Studies in mouse models have highlighted potential immune 
deviation properties of atypical bacteria that may help promote TH2 
immunity(413), and people with asthma have impaired IFN/TH1 responses to 
bacterial polysaccharides(185, 186, 189, 190). In addition, viral infection 
impairs anti-bacterial innate immune responses(414) and increases bacterial 
adherence to BECs(415). There is therefore good evidence that respiratory 
bacterial infections are more common and more severe in asthma, and that 
viral infection can increase susceptibility to bacterial infection. 
Acute wheezing episodes in children aged <3 years were associated with 
both bacterial and virus infection(118), however guidelines recommend that 
antibiotics should not be administered routinely in asthma exacerbations(416). 
Adults with asthma exacerbations treated with telithromycin showed 
statistically significantly greater reductions in asthma symptoms, improvement 
in lung function and faster recovery compared to placebo(410). However, 
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acute liver toxicity limits telithromycin to severe life threatening infections. A 
recent study reported azithromycin treatment resulted in no statistically or 
clinically significant benefit in acute asthma exacerbations in adults, however, 
for each patient randomized, more than 10 were excluded because they had 
already received antibiotics, thus widespread antibiotic usage prevented firm 
conclusions being drawn from this study(417). Further studies of antibiotics in 
adults and children, in setting of low antibiotic use, are needed to determine 
which asthma patients may benefit from antibiotic therapy during asthma 
attacks(418). 
Azithromycin treatment reduced the duration of acute episodes of asthma-like 
symptoms in 1 to 3 year old children(419). Furthermore, in 1 to 6 year old 
children with history of recurrent severe lower respiratory tract infections 
(LRTIs), azithromycin early during an apparent RTI reduced the likelihood of 
severe LRTI(420). In adults low-dose azithromycin prophylaxis for 6 months in 
subjects with exacerbation-prone severe asthma significantly reduced the rate 
of severe exacerbations and LRTIs requiring treatment with antibiotics in a 
predefined subgroup analysis of subjects with non-eosinophilic severe 
asthma(421). Further studies of antibiotics in both adults and children, in 
carefully phenotyped patient groups, are needed to determine in which 
asthma patients groups antibiotic therapy may prevent asthma attacks. 
Emerging evidence indicates that the microbiota can influence the host’s 
ability to fight respiratory infections(422), which could have profound 
implications for controlling exacerbations of asthma. Further studies of the 
effects of virus infections and of antibiotic therapy(423) on the airway 
microbiota and on risk and severity of asthma exacerbations are needed. 
The role of fungi in precipitating asthma exacerbations is likely under-
appreciated. Exacerbations of allergic bronchopulmonary aspergillosis may be 
fungal in origin, yet clinical trials are few, and with disappointing results(424). 
Epidemics of severe exacerbations in the summer months are also thought 
likely related to alternaria sensitisation and exposure(425), while epidemics of 
exacerbations related to thunderstorms may be related to pollen and/or fungal 
exposures in sensitized individuals(426). Further research into the role of 
fungi in the aetiology of asthma exacerbations is needed. 
 
4.2.3 Allergen exposure & TH2 pathways 
An important mechanistic process not completely understood is how virus 
infections exacerbate existing TH2 immunity. Risk of hospital admissions for 
asthma exacerbations increases dramatically when allergen sensitisation and 
exposure occur together with a respiratory viral infection(302, 371) and 
mechanistic studies in human and mouse models of RV infection show 
induction of the pro-TH2 cytokines IL-25 and IL-33 by RV, thus potentiating 
TH2 immunity via increased IL-4, IL-5, IL-13 and eosinophilia within the 
airways(57, 58, 186). How important human respiratory viruses impact on the 
newly identified ILC2s is very understudied, but two studies suggest virus 
induced IL-25 and IL-33 potentiated TH2 immunity via actions on these 
cells(57, 58).  
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While corticosteroid based therapies impact only moderately on the severity of 
asthma exacerbations, anti-TH2 biologics and anti-IgE therapies have shown 
a surprising efficacy(16, 18, 20, 23). Whether or not this added value is simply 
via suppressing allergen-induced TH2 pathways, or is affecting other aspects 
of virus-allergen interactions (such as restoring deficient anti-viral 
immunity(24)) with a net beneficial effect on the outcome of virus-induced 
asthma exacerbations requires further exploration. 
4.2.4 Pollution 
A short-term increase in pollution exposure levels has been associated with 
asthma exacerbations: a 10µg/m3 increase in PM2.5 correlated with 
emergency room visits and hospitalisation(427), while long-term exposure to 
NO2 increased asthma hospitalisation in the elderly(428). Exposure to low 
dose air pollution acting directly on airway cells may cause chronic production 
of inflammatory mediators in asthmatics. These mediators may cause 
increased infiltration of airways tissue by immune cells and changes to the 
airways parenchyma leading to chronic remodelling(429). This could be 
responsible for a lowered threshold for other stimuli to cause asthma 
exacerbations. Acute exposure to high levels of air pollution alone may 
directly provoke asthma exacerbations in asthmatic individuals(430) either by 
action on innate & structural cells, and/or actions on the adaptive immune 
system(431).  
There is emerging evidence providing a link between the increasing amounts 
of air pollutants/allergens in the environment and the worsening of symptoms 
in asthma(432). For example, air pollution has been linked to increases in 
hospital visits for respiratory disease(433). Synergy has also been suggested 
between air pollutants and allergens in the risk and exacerbation of asthma 
(especially in children), suggesting an advantage of avoiding co-
exposure(372, 432). 
Many epidemiological studies have identified ambient pollutant gases and 
airborne particles as risk factors for asthma exacerbations. However, the 
pollutants responsible remain unclear and causal relationships have often not 
been established. Among the most consistent observations are the direct 
effects of particle components on the generation of reactive oxygen species 
and induction of oxidative stress and inflammatory responses(434). 
4.2.5 Diet and hormones 
Individuals with ORA are at increased risk of asthma exacerbations(435).  To 
the best of our knowledge, no studies have assessed the effect of obesity on 
the innate or adaptive immune response to respiratory viruses in asthmatics. 
Given that ~80% of asthma exacerbations are virus-induced(436), ex vivo and 
human challenge studies in this area may facilitate the development of novel 
preventative or therapeutic strategies. 
Up to 20% of pregnant women with asthma experience asthma exacerbations 
during pregnancy and up to 6% require hospitalisations(325). During 
pregnancy the severity of asthma can change due to extrinsic as well as 
unknown factors. Uncontrolled asthma has a higher likelihood to deteriorate 
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during pregnancy and previous exacerbations predict emergency room visits 
during pregnancy(437), but its course is unpredictable and might even vary 
between pregnancies(325). Exacerbations have been reported to be more 
frequent during the early third trimester. Pregnancy has been reported to be 
associated with impaired anti-viral immunity in the presence(438) as well as 
absence(439) of asthma. Understanding the mechanisms that lead to 
deteriorations of asthma control during pregnancy has potential to improve 
adverse outcome associated with poor asthma control during pregnancy. 
4.2.6 Resolution of airway inflammation 
A surprising recent observation has been that protectin D1 is induced by viral 
infection(440, 441) and viral RNA-sensing TLRs(278), and protectin D1 
exhibits potent antiviral activity against influenza(440) while several resolvins 
and protectins can also enhance antibacterial defences(442). This raises the 
possibility of a dual role of SPMs in the regulation of inflammation and antiviral 
immunity in the respiratory tract with significant implications for the therapeutic 
potential of these molecules in the treatment or prevention of asthma 
exacerbations. 
 
4.2.7 Psycho-social and behavioral factors 
Stress, anxiety and depression are associated with an increased risk of 
exacerbation, less successful emergency treatment, and increased asthma 
hospitalisation rates(443, 444), and psychological co-morbidity may be 
associated with increased asthma mortality risks(445). The mechanisms 
underlying this increased risk are uncertain. Non-adherence with regular 
medication is common even in those with severe disease and exacerbation 
risk, and is associated with an increased risk of severe asthma attacks(31). 
Non-adherence occurs even in the period of deteriorating symptoms prior to 
and asthma attack(446). Risk stratification and targeted strategies to reduce 
exacerbation risk may be possible(447, 448). 
4.3 Addressing the unmet need 
 
While it is widely acknowledged that respiratory tract infections, particularly 
viral, account for the vast majority of asthma exacerbations (approximately 
80%), a number of other factors are also likely to play a role. Identification of 
these other factors is vital if we are to reduce asthma morbidity and health 
care resources utilisation. Our incomplete understanding of asthma 
exacerbation pathophysiology and mechanisms is preventing the 
development of effective treatments and preventive strategies. Many research 
programmes are seeing cross-European collaboration to integrate data, tools 
and techniques in order to explore related mechanisms and identify factors 
that play a decisive role in asthma. Similar cross-European collaboration is 
now needed to better understand aetiology and mechanism of asthma 
exacerbations. 
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At present there are few available therapies that target respiratory infections 
either non-specifically or specifically by virus type. A growing body of 
evidence suggests that augmenting deficient IFN production in asthmatic 
patients could be a novel target for therapeutic intervention in the context of 
virus induced asthma exacerbations. In addition, despite there being much 
interest and activity in developing viral inhibitors, no anti-virals have 
specifically been trialled in models of asthma exacerbations, despite the fact 
that such models exist and appear suitable(57). Again, the paucity of available 
anti-virals and a timely and effective model in which to test their efficacy must 
be considered an important unmet need. While IFN therapy is attractive in that 
it may target many viruses non-specifically, this argument can be extended to 
support the use of anti-viral therapies for asthma exacerbations. The recent 
developments in anti-viral therapy for important respiratory viruses have been 
covered elsewhere(449) and will not be systematically reviewed here. At the 
time of writing no anti-virals have specifically been trialled in models of 
asthma exacerbations, despite the multiple lines of evidence supporting the 
role of viruses as the most obvious asthma exacerbation trigger. Such studies 
are urgently needed. 
Historically there has been much interest and activity in developing viral 
inhibitors. Small molecules and antibodies to viruses themselves or their 
receptors have been developed, or are currently undergoing clinical trials for 
RV(450, 451), RSV(452, 453) and influenza(454, 455). However, there has 
been slow progress in applying these to asthma. One question that is yet to 
be satisfactorily answered is in which model should they be tested? While the 
study of natural infections requires hundreds of subjects and is therefore 
expensive and time consuming, a useful alternative could be experimental 
infection models, which are performed with as few as 30 subjects. These have 
been successfully developed for RV(57, 186), and as RV is the most 
important viral trigger, there is an urgent need for these treatments to be 
tested in experimental RV challenge models to enable careful study of both 
efficacy and mechanisms. Another important consideration is which type and 
strain of virus should be used, and whether the experimental strains available 
behave in a manner comparable to wild type strains. This case is of particular 
importance for RV. The discovery of RV group C (RV-C)(456, 457), and its 
rise as probably the most clinically important group of RVs responsible for the 
majority of asthma exacerbation admissions(458-460) makes it a clear target 
for anti-viral therapy. There are several roadblocks concerning RV-C however; 
this is a difficult virus group to culture with a unique receptor(49), few 
laboratories have this expertise and there is as yet no RV-C stock available 
for experimental human challenge. Taken together, the case for the 
implementation of anti-viral therapy in asthma exacerbations, while clearly 
supported by the available scientific evidence, is hampered by several 
practical issues that requires further funding, careful planning and co-
ordination between academia and industry to overcome. 
Viral vaccines also represent an important unmet need, with either vaccines 
for some respiratory viruses completely unavailable or when available, of 
unclear benefit. New vaccine candidates against RSV including live 
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attenuated vaccines are currently being or have recently been tested in 
clinical trials(461-463). Immunization of mice with an RV capsid protein (VP0) 
containing highly conserved regions has been shown to induce cross-reactive 
cellular and humoral immune responses and therefore such capsid domains 
may prove useful for the development of a subunit RV vaccine(464). In the 
same model, RV VP1 vaccination has also been tested and provided some 
promising results in terms of cross-serotype antibody responses for future 
vaccine development(465). Further work to develop an effective and broadly 
cross-serotype protective vaccine against rhinovirus infections is urgently 
needed. 
Regular vaccination against seasonal influenza is recommended for asthmatic 
children and adults(466, 467). A 2013 Cochrane review on the potential 
protective effect of the inactivated flu vaccine concluded that there was no 
significant reduction in the number, duration or severity of influenza-related 
asthma exacerbations in asthmatic children or adults(468). However, 
vaccinated children did display better symptom scores during influenza-
positive weeks(468). Accumulating evidence now supports the concept of 
alternative influenza virus vaccine development strategies that will stimulate 
an immune response towards the conserved stalk rather than head domains 
of the virus hemagglutinin(469, 470). Such a universal vaccine would allow 
cross-immunisation against several influenza virus subtypes; however 
protective efficacy remains to be confirmed. 
Our understanding of how asthma exacerbation frequency and severity 
relates to underlying asthma endotypes and phenotypes is also lacking. An 
important network running for over a decade is the National Institutes of 
Health-sponsored Severe Asthma Research Program (SARP), which is 
dedicated to the study of children and adults with severe asthma and aims at 
better understanding asthma endotypes with a focus on molecular and cellular 
processes. Subjects participating in the program undergo detailed 
characterization including clinical, physiological, radiological and genomic 
assessment and investigators seek to explore related mechanisms and 
identify factors that play a decisive role in disease history(471). In Europe, the 
BIOAIR and the U-BIOPRED severe asthma networks aim at improving our 
understanding of mechanisms and provide insight into endotypes or 
phenotypes such as those of frequent exacerbators(472), asthma 
exacerbation indicators(473), biomarkers(474) and pathophysiology of 
disease(475). These phenotypes need to be cross validated in different 
cohorts before they can be used to define patients. Asthma phenotyping has 
not been extensively studied among various neglected patient groups 
including smokers, drug users and the elderly. Identification of clusters may 
help recognize patients particularly prone to develop asthma exacerbations. 
Recent work towards this direction has defined phenotypic groups among 
elderly patients(476-478) and has attempted to profile asthma exacerbations 
in drug users(479). Finally, there is great potential for novel diagnostic 
technologies (in particular non-invasive techniques and biomarkers) to be 
developed to support prediction(480), assessment and management of 
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asthma exacerbations(481, 482) and future studies in the field would help 
personalize intervention strategies.  
The existing evidence points to the fact that asthma exacerbations are likely a 
result of synergistic and/or additive interactions between several factors. 
Perhaps most evidence is available for virus and TH2 interactions, and how 
these precipitate asthma exacerbations in allergic asthma. No study has yet 
linked impaired IFN responses with a known asthma phenotype, however 
most studies observed this phenomenon in atopic asthma(157, 185, 187, 391, 
393, 395). Sputum eosinophils in the past have been related to asthma 
exacerbation risk(483) and impaired IFN-λs in cultured cells negatively 
correlated with sputum eosinophilia(185) and both serum IgE and IL-4 
staining levels in biopsies(187). Mechanistically, much evidence definitively 
shows that type I and III IFNs and TH2 cytokines can exhibit potent negative 
regulation on the expression or actions of each other. IFN-α for example, can 
suppress TH2 cell polarisation in pure T cell and mixed leukocyte culture 
systems(405, 484). IFN-λ (IL-28) when given to the airways can suppress the 
generation of allergic airways inflammation in the ovalbumin sensitisation and 
challenge model in mice, which is TH2 driven(404). Conversely, crosslinking 
the FcεR1 on DCs prior to influenza virus or RV challenge down regulates 
IFN-α(395, 396); thus the overall evidence strongly underscores many 
potential mechanisms of counter-regulation of TH2 cytokines and type I and III 
IFNs. Interestingly, SOCS1, linking with impaired IFN is a TH2 inducible 
negative regulator and in the airway epithelium, correlates with serum 
IgE(399). There is still a lot to learn about how asthma exacerbations are 
precipitated, including how the underlying pathophysiology of asthma can be 
subtly affected by another insult or stimulus. This therefore represents an 
unmet need. The interactions between pathogen sensing, environmental 
microbiota and genetics are likely also important in asthma exacerbations and 
future research should explore the role of non-TH2 pathways and other 
processes including inflammasome activation in airway remodelling and how 
these processes affect steroid resistance.  
Further studies investigating the effectiveness of macrolide (including 
derivatives with and without antibiotic properties) and other antibiotics in 
treatment and prevention of acute exacerbations of asthma in adults and 
children in settings of low antibiotic usage, and studies including stratification 
on blood/sputum cell counts, are required. Further studies investigating the 
effects of viral infection on secondary disturbances of the microbiome in adult 
and children with asthma exacerbations are clearly needed, as well as studies 
investigating the mechanisms of impaired host defense against bacterial 
infections in asthma. 
Asthma exacerbations constitute major outstanding challenges to treatment. 
Given the generation of danger signals during an exacerbation, the role of 
alarmins and of ILCs in exacerbations needs to be clarified. Understanding 
the role of these new ILC populations could eventually lead to new therapeutic 
targets. Similar work is needed on the role of neuronal mechanisms and 
respiratory reflexes. 
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The role of pollution in precipitating asthma exacerbations is also incompletely 
understood. Polymorphisms in glutathione S-transferases (GSTM1 and 
GSTP1) that facilitate the elimination of reactive oxygen species have been 
associated with breathing difficulties and respiratory symptoms in asthmatic 
children following increases in ambient O3 concentrations(485) and an altered 
response to combined exposures to ragweed pollen and DEPs(486). How the 
innate immune response of asthmatics to infections is altered by air pollution 
should also be studied. Further research examining the influence of gene 
polymorphisms which could predict asthmatic patients that will benefit from 
antioxidant supplementation would be of interest.   
Patients at higher risk of exacerbations may be identified through viable 
clinical strategies, with exacerbation prevention strategies targeted to improve 
exacerbation outcomes. Psychological and behavioural factors, for example 
substance abuse(487), may increase exacerbation risk, and may be 
amenable to intervention, although the mechanisms underlying this increased 
risk are not fully understood.  
Page 43 of 91 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
© Copyright 2016,  GA- 602077 
EARIP Consortium   Version: Final 
 
   
 43  
 
5 Summary & conclusions 
Asthma research now has loftier aims than in previous times, in that we now 
aim to prevent disease occurring, to cure it when it does occur, and if these 
are not possible, to treat and control asthma to prevent progression to severe 
disease, as well as to prevent and treat acute attacks of asthma. There is also 
a focus on studying mechanisms in different asthma phenotypes, including 
atopic and non-atopic asthma, so that new therapies can be best targeted 
towards the most appropriate phenotype. 
This analysis of available literature on asthma mechanisms has delineated the 
most important unmet needs in asthma research and proposes how these 
might be addressed. A stratification into asthma onset, progression of stable 
asthma, and asthma exacerbations allows identification of where in the 
continuity of asthma research future efforts need to be directed, indicating 
who would benefit and to what extent such efforts would impact on people 
with asthma. Our review of the literature and discussions with colleagues 
have clearly identified many important unmet needs. The most important 
mechanisms involved in asthma onset, asthma progression and asthma 
exacerbation and the strength of the supportive evidence for each mechanism 
are summarised in Table 1. The most important methodologies or 
technologies that are required to beneficially impact on asthma research in 
future years are summarised in Table 2. Key unmet needs in understanding 
asthma mechanisms that we have identified are listed in Table 3 and are 
pictorially represented in Figures 1-3. These are the major areas in which 
future investment is needed to drive forward asthma research to hasten 
progress in preventing asthma developing, controlling and curing established 
asthma, and in preventing and treating asthma attacks and their associated 
morbidity and mortality. 
Firstly, we have shown that research into asthma onset suffers from several 
shortcomings in research effort. Importantly, this is an area that if addressed, 
could have the biggest impact, in both the short and long term, by preventing 
asthma occurring in the first place. We need to better understand the onset of 
both allergic and non-allergic asthma, including the role of air pollution. The 
development of new models, new sampling methods, and the structuring of 
research in productive, collaborative initiatives will deliver new information in 
the longer term and with time, new therapeutic targets for asthma inception. 
Funding this area of asthma research to amend these shortfalls should thus 
be considered a long term proposition. However, there are also more 
immediate goals to be achieved. The study of new vaccines and anti-virals, or 
application of existing ones to determine whether viruses are functionally 
associated with asthma onset could lead to exciting opportunities for asthma 
prevention. Even reducing respiratory viral infections by 20% in young infants 
could have vast financial effects on the healthcare burden associated with 
asthma. Prevention of acute respiratory viral infections could prevent wheeze 
and perhaps allergic sensitisation and asthma onset. Funding this research 
would deliver a short term gain, as anti-virals are already in phase II/III (for 
RSV) and would have to be applied to the right population at highest risk and 
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at the optimal age window  in clinical trials. For RV the prospects of pathway 
to impact are further away, as anti-viral programs are still in development. 
However vaccine candidates while still experimental, do hold promise and 
need to be prioritised.  
Targeting mechanisms of progression of stable asthma to severe disease 
requires more basic research to hasten development of a more 
comprehensive array of disease modifying therapies that better address the 
needs of severe therapy resistant asthma. The studies should include the 
different endotypes and phenotypes of asthma and specific mechanisms 
should include neural pathways, airway remodelling and the understudied 
adverse effects of asthma therapies. The longer term prospects of such 
programs would be to achieve better asthma control with better targeted novel 
treatments, to reduce progression to severe asthma and to cure established 
asthma. Other areas that need more research include the role of co-
morbidities, better clinically defined groups and models, and also aspects of 
the microbiome and bacteria-virus interactions, together with their interactions 
with pollutants. These last two subjects would benefit specifically from basic 
research including new in vitro and in vivo models. The value in funding these 
areas should be considered a longer term proposition, with the initial aim of 
developing models and techniques, and applying them to gain new disease 
insights, which would eventually lead to new targets or agents for therapy.  
Asthma exacerbations cause major morbidity, mortality and health care costs. 
Much more research funding needs to be channelled into anti-viral therapy 
and vaccine development programs to benefit asthma exacerbations, which 
have a clear viral aetiology. Funding also needs to be directed at development 
of better pre-clinical models of virus infections, and of interactions between 
virus infections, allergen exposure and airway microbes to study mechanisms 
of exacerbation. A major priority is the development of human challenge 
models in asthma with viruses, allergens and pollutants to enable 
identification of novel mechanisms of disease to lead to new therapeutic 
strategies. Development of human challenge models will also permit early 
proof of concept and proof of mechanism studies in development programs of 
novel therapeutic approaches for prevention/treatment of exacerbations. 
Funding also needs to prioritise better understanding of the mechanisms of 
increased susceptibility to viral and bacterial infection in asthma and better 
identification of the endotypes and phenotypes of asthma to which these 
specific mechanisms apply. More research is also needed to better 
understand of the interactions between TH2 pathways and anti-viral immunity 
in exacerbation pathogenesis. 
In summary, this paper describes a compelling picture of unmet need in 
asthma.  Researchers, funders and the pharmaceutical industry need to work 
together to address these important priorities to prevent, treat and eventually 
cure asthma.   
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Table 1: Mechanisms involved in asthma inception, progression 
and exacerbation 
 
Phase Mechanism & Strength of Supportive Evidence 
 
Onset Genetics∂∂,†† 
Allergen exposure & sensitization, TH2 pathways
§§§ 
Viruses‡‡,§§§,∂∂,†† 
Bacteria∂,†† 
Pollution‡,†† 
Diet§§,†† 
Hormones†† 
 Stress and psychological factors†† 
Progression Allergen exposure & sensitization, TH2 pathways
‡‡‡,§§§,∂∂∂,††† 
Bacteria†† 
Pollution‡,†† 
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Evidence: ‡in vitro model, §Animal model, ∂ex vivo patient sample, 
†longitudinal cohort or cross-sectional clinical study. 3 symbols= very strong 
evidence, 2= validated or repeatable evidence, 1= weak evidence. 
  
Airway remodeling‡‡‡,§§§,∂∂∂,† 
Resolution of inflammation‡,§§,∂∂∂,† 
Immune responsiveness vs tolerance‡,§§§,∂∂∂,† 
Adverse effects of therapies‡,† 
Diet§§,
∂∂,††
 
Hormones†† 
 Stress and psychological factors††∂ 
Exacerbation Genetics∂,† 
Allergen exposure & sensitization, TH2 pathways
‡‡,§§§,∂∂,††† 
Viruses‡‡‡,§§§,∂∂∂,††† 
Bacteria† 
Pollution‡,†† 
 Stress and psychological factors† 
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Table 2: Methodologies or technologies required to beneficially 
impact on asthma research 
 
Method Description 
NGS eQTL 
epigenetic, and 
array platforms  
RNA-seq, array techniques that capture all expressed genes in a sample. Can 
identify new mechanisms and suggest biomarkers. eQTL can relate SNPs to 
expression of genes in patient samples proving some translation of genetic effects 
GWAS and 
exome 
sequencing 
GWAS identifies SNPs associated with diseases such as asthma. An association 
of a SNP does not necessarily inform on a mechanism. Exome sequence refers to 
sequencing the exons and other specified parts of that gene, such as adjacent 
promoter sequences 
Metabolomics Analysis of biomarkers either by mass spectrometry or other protein analysis eg. 
bromotyrosine in urine 
Lipidomics Analysis of pro-inflammatory and pro-resolving lipid networks by liquid 
chromatography-tandem mass spectrometry in sputum, BAL or plasma  
Volatile organic 
compounds 
(VOCs) 
Detects organic compounds identified by mass spectrometry in non-invasive 
samples such as exhaled breath. Can detect viruses and bacteria in theory. 
Nasosorption and 
Bronchosorption 
Detects proteins in very small volumes of biological fluid. Has been applied to the 
nose and lung in detecting rare cytokines. 
Mathematical 
modelling  
Can predict the efficacy of a new therapy, or how a new model may behave. This 
may replace executing the actual experimental work. 
Machine learning Can interrogate big data sets in a free and non-hypothesis-driven manner. Can be 
useful in the formulation of new hypotheses. 
Better pre-clinical 
models  
Needed to study mechanisms of interactions between virus infections, allergen 
exposure, defective innate immunity and airway microbes in initiation, progression 
and exacerbation of asthma. 
Human challenge 
models (allergen, 
virus, pollution) 
Can permit early proof of concept and proof of mechanism in development of novel 
therapeutic approaches and enable identification of novel mechanisms of disease 
to lead to new therapeutic strategies. 
Anti-viral 
therapies and 
vaccines 
Needed for use in early life in studies on asthma prevention and for prevention and 
therapy of asthma exacerbations. 
Pre-clinical and 
clinical models of 
disease 
Needed to better understand mechanisms of neuronal dysfunction, airway 
remodelling etc in progression and severity of asthma. Pre-clinical models should 
include development of models in and reagents for guinea pigs, rats, rabbits and 
dogs as well as mice. 
Population-based 
birth cohort 
studies 
Needed to integrate genetic and epigenetic host factors with studies of virus 
infections, allergens and other environmental exposures and gut and airway 
microbes, with studies of host innate and acquired immune reactivity vs tolerance 
with systems biologic analytic methodologies, to understand mechanisms of 
asthma onset. 
Clinic/community 
based studies of 
paediatric and 
adult asthmatics. 
Needed to investigate disease mechanisms and to validate mechanistic findings 
from pre-clinical models in the human setting. 
Clinical trials Needed to investigate efficacy and mechanisms of injection and sublingual 
immunotherapy, and of novel asthma therapies. 
  
NGS = next generation sequencing    eQTL = expression quantitative trait 
loci GWAS = genome wide association studies    SNP = single nucleotide 
polymorphism 
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Table 3: Key unmet needs in understanding asthma mechanisms 
and the nature of the unmet need  
 
    
Key Unmet Need Where 
needed 
Nature of the 
unmet need* 
Mechanisms of onset of both allergic and non-allergic asthma Onset Birth cohort 
studies, pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies 
 
Role of early life viruses and bacteria as causative agents of 
asthma 
Onset Pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies 
 
Understanding mechanisms underlying the progression of 
virus-induced early wheezing to later well-defined asthma 
Onset 
Progression 
 
Birth cohort 
studies, pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies 
 
Identifying early life risk factors to enable accurate prediction of 
which early wheezers will later develop asthma to permit 
primary prevention 
 
Onset 
Progression 
 
Birth cohort 
studies, pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies 
 
Mechanism of progression to treatment refractory severe 
asthma 
Progression Pre-clinical 
models, targets, 
therapies, clinical 
studies 
 
Role of pro-TH2 cytokines IL-25, IL-33 and TSLP and of 
PGD2/CRTH2 
Onset 
Progression 
Exacerbation 
 
Pre-clinical 
models, targets, 
therapies, clinical 
studies 
 
Understanding mechanisms of development of immune 
reactivity vs immune tolerance in asthma 
Onset 
Progression 
Exacerbation 
 
Pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies 
 
Mechanisms of non-allergic asthma Onset 
Progression 
Pre-clinical 
models, targets, 
therapies, clinical 
studies 
 
Role of air pollution, occupational & other environmental 
exposures, second hand smoke 
Onset 
Progression 
Exacerbation 
 
Pre-clinical 
models, targets, 
therapies, clinical 
studies 
 
Protective vs pathogenic role of gut and lung microbiomes Onset, Pre-clinical 
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Progression, 
Exacerbation 
 
models, targets, 
clinical studies 
 
 
New anti-viral therapies and vaccines Onset, 
Exacerbation 
Pre-clinical 
models, therapies, 
clinical studies 
 
Understanding mechanisms of increased susceptibility to viral 
and bacterial infection in asthma 
 
Progression 
Exacerbation 
 
Pre-clinical 
models, novel 
targets, new 
therapies 
 
Understanding asthma phenotypes expressing deficient anti-
viral immunity, and the mechanisms involved 
 
Progression 
Exacerbation 
 
Pre-clinical 
models, novel 
targets, new 
therapies 
 
Understanding mechanisms of action of pro-resolving lipid 
mediators in asthma 
Progression 
Exacerbation 
 
Pre-clinical 
models, novel 
targets, new 
therapies 
 
Understanding neural pathways Onset, 
Progression 
Exacerbation 
 
Pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies 
 
Understanding role of obesity, diet, hormones & pregnancy Onset, 
Progression 
Exacerbation 
 
Pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies  
 
Mechanisms of airway remodelling 
 
Progression Pre-clinical 
models, novel 
targets, new 
therapies, clinical 
studies  
 
Mechanisms underpinning relationship between psychological 
factors and asthma 
Onset, 
Progression 
Exacerbation 
Pre-clinical 
models, clinical 
studies 
 
Mechanisms of adverse effects of asthma therapies Progression, 
Exacerbation 
 
Pre-clinical 
models, clinical 
studies 
 
Translating genetic findings to disease mechanisms Onset 
Exacerbation 
Pre-clinical 
models, clinical 
studies 
 
* Pre-clinical models may include in vitro studies in human cells as well as in vivo studies in animal 
models, clinical studies may include human challenge (virus, allergen, pollution) models as well as 
mechanistic and interventional clinical studies.  
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Figure legends 
 
Figure 1. Major mechanisms of asthma onset. The major cell types, cytokines 
and mechanisms involved in asthma onset are depicted, with major 
mechanisms/research areas requiring substantial further investment 
highlighted in boxes.  
 
Figure 2. Major mechanisms of asthma progression and severity. The major 
cell types, cytokines and mechanisms involved in asthma progression are 
depicted, with major mechanisms/research areas requiring substantial further 
investment highlighted in boxes.  
 
Figure 3. Major mechanisms of asthma exacerbations. The major cell types, 
cytokines and mechanisms involved in asthma exacerbations are depicted, 
with major mechanisms/research areas requiring substantial further 
investment highlighted in boxes.  
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Major mechanisms of asthma onset. The major cell types, cytokines and mechanisms involved in asthma 
onset are depicted, with major mechanisms/research areas requiring substantial further investment 
highlighted in boxes  
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Major mechanisms of asthma progression and severity. The major cell types, cytokines and mechanisms 
involved in asthma progression are depicted, with major mechanisms/research areas requiring substantial 
further investment highlighted in boxes.  
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Major mechanisms of asthma exacerbations. The major cell types, cytokines and mechanisms involved in 
asthma exacerbations are depicted, with major mechanisms/research areas requiring substantial further 
investment highlighted in boxes.  
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